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 Abstract 
In biomedical studies, the treatment main effect is often expressed in terms of an 
“average difference.” A treatment that appears superior based on the average effect may not be 
superior for all subjects in a population if there is substantial “subject-treatment interaction.” A 
parameter quantifying subject-treatment interaction is inestimable in two sample completely 
randomized designs. Crossover designs have been suggested as a way to estimate the variability 
in individual treatment effects since an “individual treatment effect” can be measured. However, 
variability in these observed individual effects may include variability due to the treatment plus 
inherent variability of a response over time. We use the “Neyman - Rubin Model of Causal 
Inference” (Neyman, 1923; Rubin, 1974) for analyses. 
This dissertation consists of two parts: The quantitative and qualitative response analyses. 
The quantitative part focuses on disentangling the variability due to treatment effects from 
variability due to time effects using suitable crossover designs. Next, we propose a variable that 
defines the variance of a true individual treatment effect in a two crossover designs and show 
that they are not directly estimable but the mean effect is estimable. Furthermore, we show the 
variance of individual treatment effects is biased under both designs. The bias depends on time 
effects. Under certain design considerations, linear combinations of time effects can be 
estimated, making it possible to separate the variability due to time from that due to treatment. 
The qualitative section involves a binary response and is centered on estimating the 
average treatment effect and bounding a probability of a negative effect, a parameter which 
relates to the individual treatment effect variability. Using a stated joint probability distribution 
of potential outcomes, we express the probability of the observed outcomes under a two 
treatment, two periods crossover design. Maximum likelihood estimates of these probabilities are 
found using an iterative numerical method. From these, we propose bounds for an inestimable 
probability of negative effect. Tighter bounds are obtained with information from subjects that 
receive the same treatments over the two periods. Finally, we simulate an example of observed 
count data to illustrate estimation of the bounds. 
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 Abstract 
In biomedical studies, the treatment main effect is often expressed in terms of an 
“average difference.” A treatment that appears superior based on the average effect may not be 
superior for all subjects in a population if there is substantial “subject-treatment interaction.” A 
parameter quantifying subject-treatment interaction is inestimable in two sample completely 
randomized designs. Crossover designs have been suggested as a way to estimate the variability 
in individual treatment effects since an “individual treatment effect” can be measured. However, 
variability in these observed individual effects may include variability due to the treatment plus 
inherent variability of a response over time. We use the “Neyman - Rubin Model of Causal 
Inference” (Neyman, 1923; Rubin, 1974) for analyses. 
This dissertation consists of two parts: The quantitative and qualitative response analyses. 
The quantitative part focuses on disentangling the variability due to treatment effects from 
variability due to time effects using suitable crossover designs. Next, we propose a variable that 
defines the variance of a true individual treatment effect in a two crossover designs and show 
that they are not directly estimable but the mean effect is estimable. Furthermore, we show the 
variance of individual treatment effects is biased under both designs. The bias depends on time 
effects. Under certain design considerations, linear combinations of time effects can be 
estimated, making it possible to separate the variability due to time from that due to treatment. 
The qualitative section involves a binary response and is centered on estimating the 
average treatment effect and bounding a probability of a negative effect, a parameter which 
relates to the individual treatment effect variabil
of potential outcomes, we express the probability of the observed outcomes under a two 
treatment, two periods crossover design. Maximum likelihood estimates of these probabilities are 
found using an iterative numerical method. From these, we propose bounds for an inestimable 
probability of negative effect. Tighter bounds are obtained with information from subjects that 
receive the same treatments over the two periods. Finally, we simulate an example of observed 
count data to illustrate estimation of the bounds. 
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CHAPTER 1 - Introduction 
1.0: An Overview 
In clinical trials and other scientific studies comparing two or more treatments, the 
treatment effect is often expressed in terms of an “average” effect although the importance of 
variability of the effect has been recognized. A treatment that appears superior based on a 
general population average effect may not be superior for all subjects in a population. Less focus 
has been put on assessing the variability of the individual treatment effects or “subject-
treatment” interaction (Gadbury, 2004) within the population. If substantial, this variance is 
worth considering in efficacy and safety measures. This dissertation focuses on estimating the 
individual treatment effect variability and the probability of a negative treatment effect for both 
the quantitative and qualitative responses using crossover designs. The “Rubin Model of Causal 
Inference” (Holland, 1986) which employs the “potential outcomes” framework is used.  
 
1.1:  The Potential Outcomes Framework  
Briefly, let iX  and iY  denote the response when unit (subject) i  receives treatment T  
and control C  (say) respectively. The bivariate pair ( ),i iX Y  are potential outcomes (Rubin, 
2005, Neyman, 1923) for unit i .  Only one of iX  or iY  is observed for the thi  unit at a given 
time since we cannot expose a subject to both treatments at the same time. This is called the 
“fundamental problem of causal inference” (Holland, 1986). The unobservable outcome in the 
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pair ( ),i iX Y
 
is sometimes called counterfactual (Glymour, 1986). Note that this bivariate 
specification holds only when we are comparing two treatments. For a study comparing t  
treatments, the potential outcomes would be a vector containing t  outcomes (rather than two) 
and only one of the t  outcomes would be observable for a given subject at a particular time. The 
next section, expands on the Rubin model.  
 
1.1.1:  The Rubin Model for Causal Inference 
Often called the Neyman-Rubin Model of causal inference, the framework originated with 
Neyman’s (1923) model (in the context of completely randomized experiments) whereby each 
unit had two potential outcomes with only one of the two observable. Later Rubin (1974, 2005) 
and others developed the model into a general framework for causal inference in relation to 
behavioral science. Holland (1986) also wrote an influential paper using this model emphasizing 
the philosophical aspects of the framework. On the basis of the work done by Neyman and 
Rubin, the model is sometimes referred to as the “Neyman-Rubin Model” or sometimes 
“Neyman-Rubin-Holland Model” or simply the “Rubin Model.” Suppose we are to compare 
these two treatments, the Rubin Model specifies that the true treatment effect for unit i  is given 
as i i iD X Y= − . This treatment effect applies to both quantitative and qualitative responses. This 
Rubin Model assumes the “stable unit treatment value assumption” (SUTVA, Rubin 1980, 
1990). Essentially, SUTVA has two assumptions: (1) there is only one version of a specific 
treatment, either T or C, assigned to all subjects (for example, two or more manufacturers are 
assumed to produce the exact drug assigned to the subjects) and (2) there is no interference 
between subjects – that is, the value of each subject’s potential outcome does not depend on the 
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treatment assigned to other subjects.  When SUTVA is violated, “an experiment will not yield 
unbiased estimates of the causal effect of interest” (Sekhon, 2007, p.5). An added assumption in 
this dissertation is that, the potential outcomes is not affect by “how or whether we try to learn 
about it” Rubin (2005, p.323). In general, when the causal inference assumptions are defied, 
randomization of subjects to treatments and the subsequent analysis becomes very complicated. 
In this dissertation, we will be using the Rubin Model along with the SUTVA conditions. 
Furthermore, we assume there are carryover effect, no covariates and no missing values or if 
there are, then, the values are missing completely at random (MCAR, Little and Rubin 2002). 
 
1.1.2:  The Definition of Individual Effects, Treatment Effect Homogeneity/Heterogeneity 
and Subject-Treatment Interaction  
Using the Rubin Model i i iD X Y= −  for the 
thi  individual, the individual treatment effect 
may be defined as the difference in the response on an individual subject as a result of receiving 
treatment T  versus C  at a given time. This is unlike the average effect which is the mean 
response due to both treatments. Since a subject receives one treatment at a time, this individual 
treatment effect is not observable. When the focus is on an overall mean effect, the difference 
i i iD X Y= −  is implicitly assumed constant for all individuals in the population when the mean 
effect is being tested using Fisher’s Randomization Test (Fisher, 1935; Rubin, 1980). This 
assumption is what is referred to as treatment (effect) homogeneity (Longford, 1999). Kravitz et 
al. (2004, p.660) defined treatment heterogeneity as “…patient diversity in risk of disease, 
responsiveness to treatment, vulnerability to adverse effects, and utility for different outcomes.” 
They further argue that individual treatment effect heterogeneity can lead to outcomes with a 
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mixture of “substantial benefit for some, little benefit for many and harm for a few” Kravitz et al. 
(2004, p.661).  The variable treatment effect for each subject results in what is referred to as 
subject-treatment interaction (Marshall, 1997; Longford, 1999). Senn (2001, p. 1481) defines 
subject-treatment interaction as “the extent to which the difference between treatments differ 
from one patient to another” or equivalently, “the extent to which the difference between patients 
being given the same treatment depends on treatment given.”  
This dissertation consists of two parts: The quantitative and qualitative parts. The 
quantitative part of the dissertation seeks to estimate individual treatment effect variability and to 
separate such variability from variability due to time effects in multiple time point trials. The 
method of potential outcomes will be used to achieve this goal. Meanwhile, in the qualitative 
parts, focus will be placed on the average treatment effect and the “probability of negative 
effect” – a component which implicitly reflects individual treatment effect variability. If 
substantial, the individual effect variability or the probability of negative effect is worth 
considering in conclusions about effectiveness and safety of the treatment being analyzed. 
 
1.2:  Background 
The effects of many treatments across individuals may vary widely. When such variation 
is present, there may be non-negligible proportion of a population that has an adverse effect of a 
treatment despite studies showing the effect of treatment to be beneficial, “on average.” 
Complicating the detection of the individual effect variability is the fact that some response 
measures, such as blood pressure, vary widely at different time points. Determining whether a 
change in a response is due to the effect of a treatment or just due to natural variation of a 
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response over time can be challenging.  A case in point is the controversy surrounding Dietary 
Approaches to Stop Hypertension (DASH), a salt and blood pressure or hypertension study 
(Obarzanek et al, 2003).  
The DASH study is a widely published clinical trial that suggests that systolic blood 
pressure (SBP) could be reduced by eating diets rich in fruits, vegetables and with low-fat diary. 
Five institutions collaborated in the original study in which there were two treatments, a DASH 
diet and a control diet, each delivered at three levels of salt at 8g(high-H) a day or 140mmol/d, 
6g a day or 104mmol/d (Medium-N: government’s recommendation) and 4g(Low-L) a day or 
62mmol/d. The response variable was the mean of 5 pairs of SBP measurements for each of the 
188 participants taken over the final 9 days of each 30-day feeding period. Obarzanek et al 
(2003) concluded that most of the variability in SBP was caused by “other factors’ than salt 
intake. They also pointed out that the variability depends on the group of individuals involved, 
suggesting a case for the introduction of covariates.  
DASH study is one of many that may involve individual treatment effect heterogeneity or 
variability. Considering the controversies and limitations of the DASH-Sodium Trial, the 
knowledge and the ability to estimate variability in an individual treatment effect using the 
appropriate design is of critical importance. A treatment that appears superior based on the 
average effect may not be superior for all subjects in a population if there is substantial 
individual treatment effect variability expressed in terms of “subject-by-treatment” interaction. 
This interaction may consist of component factor-by-treatment interactions like “gene-by-
treatment” interaction, “social status-by-treatment” interaction and so forth. 
Cross-over designs have been suggested as a way to estimate the variability in individual 
treatment effects since some degree of a treatment effect’s “separability” from effects of time can 
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be achieved. The DASH-Sodium results suggests that variability in observed individual effects 
may include variability due to the treatment plus inherent variability of a response over time and 
would require special types of cross designs to identify and estimate.  
Disentangling variability due to treatment effects from variability due to time effects is 
challenging. Essentially, we will analyze the individual treatment effects as a random variable 
(rather than a constant effect) for a specified population of subjects and it suffices to look at the 
variance as well as mean effect parameters (Longford, 1999).  
We present a method of potential outcomes analyses using various two treatment designs. 
For instance, we use the two treatments, three periods crossover design – a class of repeated 
crossover design or the “n-of-1” trial (Senn, 2001). This dissertation work builds on earlier work 
by Gadbury and others (2000, 2001, 2004). A parameter quantifying subject-treatment 
interaction is inestimable in two treatments, two period balanced crossover designs. The two 
treatments, three periods design used here extends the initial work on the two treatments, two 
periods design by Gadbury et al. (2004). The design used here permits certain inseparable effects 
or a combination of effects to be measured or estimated.  
The first part of the research (Chapter 2 and 3) is based on quantitative treatment 
response variables. In the next Section 1.3, we present previous work involving the complete 
randomized design and the two treatments, two periods crossover designs. Section 1.4 introduces 
some population types to be used in the analyses presented in chapter 2 and 3. Chapter 2 deals 
with an extended two treatments, two periods design, a design whereby some subjects stay on the 
same treatments over the two periods. In chapter 3, we extend the analyses to a three period 
design for quantitative response and in chapter 4, we further the work done with qualitative 
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responses in Gadbury et al (2004), summarily presented in Section 1.3.3.  Chapter 5 sums up the 
dissertation work and lays out some future challenges and research opportunities. 
 
1.3:  Previous Work on Subject-Treatment Interaction 
Senn (2001, Vol. 35) outlined the various error terms and sources of variability (Table 
1.1) that are identifiable with different types of designs (Table 1.2).  With a 2 treatments, 2 
period cross-over design, it is impossible to separate the variability due to patient-by-treatment 
interaction from the within-patient variation even in the absence of carryover effects but a 
repeated period crossover design will make it possible for such effects to be separable. In the 
table below, Senn (2001, Vol. 35) describes and lists the effects that are identifiable plus the 
various errors terms. 
Table 1.1: Sources of Variation in Clinical Trials 
Label Source 
 
Description 
A Between Treatments 
 
The average difference between treatments over all 
randomizations (and hence over all patients). The ‘true’ mean 
difference between treatments 
B Between patients 
 
The average difference between patients. (Averaged over both 
experimental and control treatments.) 
C 
Patient-by- treatment 
interaction 
 
The extent to which the difference between treatments differ 
from one patient to another. (Equivalently, the extent to which 
the difference between patients being given the same treatment 
depends on treatment given.) 
D Within-patient error 
The variability shown from treatment period to   treatment period 
when the same patient is given the same Treatment 
Source: Senn, S. (2001, p.1481). “Individual Therapy: New Dawn or False Dawn?” British Medical Journal (BMJ), 
Vol. 35 
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Table 1.2: Indentifiability and Clinical Trials 
Type of Trial                          Description                     Identifiable Effects            Error Term 
 
Parallel                                     Each patient receives one            A                              B + C+ D 
                                                 treatment 
 
Cross-over                                Each patient receives each           A and B                   C + D 
                                                 treatment in one period only 
 
Repeated period cross-over      Each patient receives each            A and B and C         D 
(Sets of n-of-1 trials)                treatment in at least two periods 
 
Source: Stephen Senn (2001, p. 1481). “Individual Therapy: New Dawn or False Dawn?” British Medical Journal 
(BMJ), Vol. 35. Total Error E = A+B+C+D 
 
In another paper, Senn (2001, Vol. 329) further echoes the ideas presented on Table 1.2 
and recommends random effect models in the analysis of repeated periods cross-over design to 
identify individual effect variability represented by the subject-by-treatment interaction, though 
as will be shown, assumptions are still needed and these assumptions are not always obvious 
without the structure of potential outcomes. Thus, it appears worthy to consider a repeated period 
crossover design using potential outcomes. One particular example  where a repeated period 
crossover design was used to study subject-by-treatment interaction is the double blind 
randomized comparison of paracetamol 1g b.i.d. (bis in die – twice a day)  and diclofenac 50 mg 
b.i.d. osteoarthritis study reported by March et al.(1994), although their analysis did not used the 
random effect model nor were potential outcomes considered.  
 
1.3.1: Two treatment completely randomized designs 
Let iX  and iY  denote quantitative or categorical outcomes when unit (subject) i  receives 
treatment T  and C  respectively for 1,2,...,i N= . The set of N potential outcomes has the form 
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given below (left bracket), which after treatment assignment, produces observed outcomes of the 
form shown (right bracket), and where the “?” represents an unobservable potential outcome 
(Gadbury et al., 2004). 
1
21 1
1
?
?
?
?
Treatment Assignment
NN N
N
X
YX Y
YX Y
X
−
 
 
   
   
→    
   
 
 
  
 
This two treatments randomized complete design assumes SUTVA. That is, subject’s 
response to a particular treatment stays the same regardless of what treatment other subjects 
receive or whether there may be different types of treatments.  
The individual treatment effect i i iD X Y= −  cannot be observed because only one of the 
iX  or iY  is observed for an individual at a particular time. So, some have proposed crossover 
design, whereby, the treatment effect for an individual can be observed. But the observed 
treatment effects also contain time effects. The next section explores this in a 2 treatments, 2 
periods crossover design.   
 
1.3.2:  Initial Work on Two Period (TC CT) Cross-Over Designs for Quantitative Response 
Gadbury (2001) developed some initial results for a two treatment balanced cross over 
design. Accordingly, consider two treatments labeled T and C in a 2 period design                                    
 
                                 
1
2
                      Period
                       1    2
Sequence     
T C
C T
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Assume a finite population of 2n  subjects used to define the potential outcomes. We 
assign n  subjects to each sequence. Potential outcome framework for the 2n  subjects is given 
by 
1 1 1 1 1 1 1 1
2 2 2 2 2 2 2 2
1 2
1
2 n n n n n n n n
Subject Time Time
X t Y X t Y
n X t Y X t Y
τ τ
τ τ
− − + +
− − + +
    
 
 
with potential outcomes ( )1 1,  i iX t Y τ− −  for period 1 and ( )2 2,  i iX t Y τ+ +  for period 2. 
Furthermore, define the “true” mean individual treatment effect for the thi  subject as the 
average of the two true treatment effects over the two time periods so that the time effects cancel, 
that is, the “true” finite population mean treatment effect is given as D X Y= − , where 
2
1
(1 / 2 )
n
i
i
X n X
=
= ∑  and 
2
1
(1/ 2 )
n
i
i
Y n Y
=
= ∑ .  
The true finite population variance of the individual treatment effects, denoted 2DS , is given as 
22 2
1
1( ) ( ) ( )
2
n
D iiS Var X Y Var D D Dn =
= − = = −∑  
The observed treatment effect for the thi  subject is  
( ) ( ) ( ) ( ) ( )1i i i i i i i i i i id X t Y T X t Y Tτ τ   = − − + + + − − −     
where iT  represent the random assignment to sequence with 1 or 0iT =  for assignment to T-C 
or to C-T, respectively. 
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It was shown that, the estimated “observed” mean treatment effect d is unbiased for 
D with respect to the randomization distribution for iT . Gadbury (2001) defined a reasonable 
estimator of 2DS  as 
2
dS  where ,  ( )2 22
1
1
2
n
d i
i
S d d
n
=
= −∑  and showed that, 
( ) ( ) ( )22 2 22 12 1d D tnE S S S tn τ τ+−= + + +−  
where, 2tS τ+  is the finite population variance of the sum of time effect terms, t τ+  and t and 
τ are the finite population averages of t and τ . The bias term is given as 
( ) ( )222 1
2 1 t
n
bias S t
n
τ τ+
−
= + +
−
 
This bias is always positive and will only be zero if 0t τ+ = , in which case, 2dS  estimates 
2
DS exactly. In the next part, we present the previous work on qualitative (binary) response 
variable. 
 
1.3.3:  Initial Work on Two Period (TC – CT) Cross-Over Designs for Binary Response  
Suppose that the outcome 1 denotes a “success” and 0, a “failure”, the following table 
provides the assumed bivariate distribution of potential outcomes in an infinite population, as 
presented in Gadbury et al. (2004): 
         
( ) ( ) ( ) ( ) ( )
( ) 1 2 3 4
, 0,0 0,1 1,0 1,1
,
x y
P X x Y y pi pi pi pi= =
                           where  
4
1
1i
i
pi
=
=∑ . 
They noted that the individual treatment effect variable D X Y= −  is discrete with possible 
values 0, -1, and 1 with probabilities 1 4 2 3,   and pi pi pi pi+  respectively. Subject-Treatment 
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interaction is present in the population unless one of these three probabilities, 
1 4 2 3,   and pi pi pi pi+ , is equal to one.  A detrimental or unfavorable effect means that 1D = − . 
Thus, the proportion of the population experiencing a negative effect is 2pi . They showed that, 
the mean treatment effect is given by ( ) ( ) 3 2E D E X Y pi pi= − = − . The population parameters 
,  ( 1,2,3,4)i ipi =  are by themselves, nonestimable. In addition, the constructed bounds for the 
risk involved in administering the treatment T to the population were given as 
( ) ( )( )2 3 2 3 4 2 4max 0,  min 1 ,  pi pi pi pi pi pi pi− ≤ ≤ − + + . 
Gadbury et al., (2004) also considered a matched-pairs design and showed that a design 
that includes some pairs receiving the same treatment can tighten the bounds for 2pi , though the 
tightness depends on ‘quality of matching’ criteria that cannot directly be assessed from 
observable outcomes. 
 
Remark 1.3.1 
In the next chapter , we focus on the TC – CT – TT – CC design for quantitative response 
variable. Thus, in chapter 2, we let some subject stay on the same treatment (TT and CC) over 
the two periods. This is an extension of the TC – CT crossover design presented in Sections 1.3.2 
above. These subjects will provide the additional information necessary to estimate the bias 
( ) ( )222 1
2 1 t
n
bias S t
n
τ τ+
−
= + +
−
 and subsequently, the true variance of the individual treatment 
effects, 2DS , using a certain assumption. These estimations were not possible with the previous 
  
 13 
TC – CT crossover design because 2tS τ+  (and hence
( ) ( )222 1
2 1 t
n
bias S t
n
τ τ+
−
= + +
−
) could not 
be estimable, without even more restrictive and perhaps implausible assumptions.  
In both chapters 2 and 3 involving quantitative response variable, we will be working 
with three types of populations described in the next subsection. In chapter 4 that considers a 
binary response, the multinomial population model is used. 
 
1.4: A List of Populations Used For the Quantitative Analysis 
For a smooth understanding of the quantitative analyses, we list three types of 
populations used herein.  
1). First, a finite population of potential outcomes from which we define a true individual 
effect, D , with finite population parameters D  and 2DS .  We begin the analyses with this finite 
population of potential outcomes. 
2). Second, a population distribution of time effects designated t  and τ . The population will 
have parameters tµ , τµ , 2tσ  and 2τσ . This population will be used when estimation of a bias 
term comes to focus.  
3). Third, a “super – population” (Smith and Sugden, 1988) distribution for treatment effects. 
This population will be used to determine the distribution of D  with population parameters 
Dµ and 2Dσ . The population of treatment effects will be used in the illustrative examples. 
Again, note that these lists of populations will be useful with the quantitative response 
only. The qualitative analysis will make use of a binomial or multinomial population model. 
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CHAPTER 2 -  A Two Period, Two Treatment Design for 
Quantitative Responses 
2.1:  A Two Period  − − −TC CT TT CC Design for Quantitative Responses 
Previously, Gadbury (2001) worked on the two period TC and CT design. In this section, 
we will extend this design to include TT and CC. 
Accordingly, consider two treatments labeled T and C in the following 2 periods designs: 
                                                      
                                                                                  
 
                                                                                                                                         
Design 2.1.1: Two sequence-two periods.                      Design 2.1.2: Four sequence-two periods.                                                      
                     
Using a slightly different estimator of the true individual treatment effect variability, Gadbury 
(2001) developed some initial results for Design 2.1.1(see section 1.3.2). However, it is 
impossible to estimate 2DS  with Design 2.1.1. But, if we allow some subjects to stay on the same 
treatments as shown in Design 2.1.2 (sequences 3 and 4), estimation of 2DS  is possible, with 
certain assumptions, through estimation of linear combinations of time effect parameters.  Note 
that we cannot observe the treatment effects for subjects in sequences 3 and 4 of Design 2.1.2. 
Sequence
Period
  
                          1     2
1
2
        
3
4
T C
C T
T T
C C
1
2
Period
 Sequence
                       1    2
     
T C
C T
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Those subjects will provide the time effect information necessary to estimate 2DS  from Design 
2.1.1. 
Following the Gadbury (2001), assume we have finite population of 2n  subjects from 
which we define our potential outcomes framework as shown below. 
1 11 1 11 1 12 1 12
2 2 1 2 2 1 2 2 2 2 2 2
Subject Period 1 Period 2
1
2 n n n n n n n n
X t Y X t Y
n X t Y X t Y
τ τ
τ τ
+ + + +
+ + + +
    
 
with potential outcomes ( )1 1,  i i i iX t Y τ+ +  for period 1 and ( )2 2,  i i i iX t Y τ+ +  for period 2 
( )1, 2,..., 2i n= . iX  and iY  are the average responses to treatments T and C , respectively, over 
the two time periods for subject 1,2,...,2i n= ; ijt (associated with treatment T ) and 
ijτ (associated with treatment C )  are the time effect parameters for subject 1,2,...,2i n=  in 
period 1,2j = . We assume 1 2 1 20 and 0i i i it t τ τ+ = + = . 
 
Remark 2.1 
The symbols of the time parameters used here is a slight deviation from those in Gadbury 
(2001) where time parameters are simply denoted  and i it τ . The reason for specifying the time 
parameters as  1 2 1 2,  and ,  i i i it t τ τ  is to synchronize the symbols with those of a more complex 
design (to be seen in chapter 3). Nonetheless, the results will not be affected by this change since 
it may be assumed that 1 2 1 2 and i i i i i it t t τ τ τ= = − = = −  
Using Design 2.1.2, the observed outcome framework is given as 
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1 2
1 2
1 2
1 2
                              Period
                           1              2
  
  
Sequence  
  
  
i i i i
i i i i
i i i i
i i i i
X t YT C
Y X tC T
X t X tT T
Y YC C
τ
τ
τ τ
+ +
+ +
+ +
+ +
 
Define the true individual treatment effect on the thi  subject as 
2 2
1 1
i i i ij ij i i
j j
D X Y t X Yτ
= =
= − + − = −∑ ∑  . iD  is not observable for any i . The true finite 
population mean effect of treatment, D  is given as D X Y= −  where 
2
1
(1 / 2 )
n
i
i
X n X
=
= ∑  and 
2
1
(1/ 2 )
n
i
i
Y n Y
=
= ∑ .  Define the true finite population variance of individual treatment effects, 
denoted 2DS , as  
22 2
1
1 ( )
2
n
D iiS D Dn =
= −∑  
Let 1iγ  be an indicator variable which takes the value 1  when the thi  subject is in 
sequence 1, for 1,2,...,2i n= .  Observe that, 1 Binomial(1,1 / 2)iγ ∼ .  The observed treatment 
effect for the thi  subject under Design 2.1.2 is   
( ) ( ) ( ) ( ) ( )1 2 1 2 1 11i i i i i i i i i i id X t Y X t Yτ γ τ γ   = + − + + + − + −    . 
This simplifies to 
                             ( ) ( ) ( )2 1 1 2 1 2 1i i i i i i i i i id X Y t t tτ τ τ γ= − + − + − + −  
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Thus, ( )1  1 1/ 2iP γ = = . In addition, ( )1 1/ 2iE γ =  and ( )1 1/ 4iVar γ = .  
If i i′=  then ( ) ( ) ( )21 1 1 1 1/ 2i i i iE E Eγ γ γ γ′ = = = .   
For i i′≠ , ( ) ( )1 1 1 1 1 11, 1  2 2 1i i i i
nE P
n
γ γ γ γ
′ ′
− 
= = = =  
− 
when subjects i  and i′  are in 
sequence 1 and ( )( )1 1 11  2 2 1i i
nE
n
γ γ
′
 
− =  
− 
when subjects  and i i′ are in sequence 1 and 
sequence 2, respectively. 
 
Proposition 2.1 
The observed mean treatment effect, d ,  is an unbiased estimate of the true mean 
treatment effect D . That is, ( )E d D= , where expectation is taken over all possible 
randomizations 1iγ . 
Proof: 
 
 
 
 
 
Note that the proof was established with the fact that ( )1 1/ 2iEγ γ =  and the assumptions 
that
2 2
1 1
0 and 0ij ij
j j
t τ
= =
= =∑ ∑  for subject 1,2,...,2i n=  and period 1,2j = . 
( ) ( ) ( ) ( )( )
( )
2 1 1 2 1 2 1
1
2
1
1
2
1
          
2
          
          
n
i i i i i i i i i
i
n
i i
i
E d X Y t t t
n
X Y
n
X Y
D
γ τ τ τ γ
=
=
= − + − + − + −
= −
= −
=
∑
∑
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Define the observed individual treatment effect variability, denoted 2dS , as  
( )2 22
1
1
2 1
n
d i
i
S d d
n
=
= −
−
∑ . 
 
Proposition 2.2 
For each subject, the observe treatment effect variability is not an unbiased estimator of 
the true individual treatment variability. That is,  
2 22 1
2 d D
nE S S Bias
n
− 
= + 
 
 
where ( )222 12 tnBias S tn τ τ+−  = + +   , 2tS τ+  and  ( )
2
1 1
1
1
2
n
i i
i
t t
n
τ τ
=
+ = +∑  are the finite 
population variance and finite population mean of the sum of time effect terms t τ+ . 
Expectation is taken over all possible randomization of the 2n  subject. 
Proof:  See Appendix A 
 
Remark 2.2: 
With Design 2.1.1, it is impossible to estimate 2DS  due to the presence of 
2
tS τ+ and t τ+  
in the bias formula. 2tS τ+ and t τ+ cannot be estimable because the combination of time effect 
parameters, t τ+ , cannot be observed for any individual. In order for 2DS
 
to be estimated, 
consider a design where some subjects stay on the same treatments as given in Design 2.1.2. In 
the next section, Design 2.1.2 is used to estimate 2DS  with a particular assumption. 
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Estimation of 2DS  
In Design 2.1.2, we let some subjects stay on same treatments as provided by sequences 
TT and CC . These subjects provide no information about the individual treatment effect and are 
used here to provide useful information about the combination of time effects t τ+ . This 
information will be used to estimate the finite population variance 2tS τ+ and the finite population 
mean t τ+  parameters. Sequences TC  and CT  considered together will give us same 
information as obtained above.  
Assume a total of 2n  subject where 1,2,...i n=  subjects are assigned to each of 
sequences TT and CC . The observed outcome is   
1 2
1 2
                              Period
                           1              2
Sequence  i i i i
i i i i
X t X tT T
Y YC C τ τ
+ +
+ +
 
From the TT and CC  randomizations, we obtain 2 1i it t− and 2 1i iτ τ−  respectively. Using the 
assumption that 
2
1
0ij
j
t
=
=∑  and 
2
1
0ij
j
τ
=
=∑ , we obtain 12 it  and 12 iτ from which we get the 
combination ( )t τ+  where 1
1
1 n
i
i
t t
n
=
= ∑  and 1
1
1 n
i
in
τ τ
=
= ∑  are the observed mean time effects 
obtained from those who stayed on TT and CC
 
respectively. Thus, we denote an estimate of 
t τ+  by t τ
∧
+  where ( )t tτ τ
∧
+ = + .   
Define 2ˆtS τ+  as the finite population variance of t τ+ . 
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Assuming t and τ  are independent, we can estimate 2tS τ+ by 
2
ˆ
tS τ+ . Plugging-in the estimated 
bias, we have  
2
22 1
ˆ
2 t
nBias S t
n
τ τ
∧∧
+
  
−  
= + + 
  
  
 
where  ( )t tτ τ
∧
+ = + . 
Suppose we designate the estimated true individual treatment effect variability as 2ˆDS , 
2
ˆ
DS is 
given as 
2 22 1
ˆ
2D d
nS S Bias
n
∧
−
= −  
Remark 2.3 
Despite the added information from the TT – CC design, it is worthwhile noting that 
estimation of 2DS , denoted 
2
ˆ
DS , was possible because of the important assumption of 
independence between t and τ . Without this assumption only bounds for 2DS  can be estimated 
(as was mentioned in Gadbury, 2001, though Gadbury did not produce the bounds nor were the 
TT CC sequences considered.  
 
2.2:  A Two Period     − − −TC CT TT CC Design with Binary Responses 
This is similar to the topic in Section 2.2 except for binary responses. Some related work 
was done by Gadbury et al., (2004) for matched-pairs, but exchangeability assumptions that were 
relevant for matched-pairs do not necessarily hold when subjects are matched to themselves over 
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time periods. Thus, the details in Gadbury et al., (2004) will be modified to redefine a 
‘successful’ response to treatment and to deal with time effects as opposed to matching criteria in 
matched-pairs. Chapter 4 provides the detailed analyses for this two period TC – CT – TT – CC 
design with binary responses. In the next chapter, we analyze a two treatment, three period 
crossover design. This design facilitates the estimation of the individual treatment effect 
variability, a task that could not be achieved with the two periods TC – CT crossover design 
considered in chapter 2. 
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CHAPTER 3 - Chapter Three: A Three Period, Two Treatment 
Design with Quantitative 
3. 0.  A Three Period, Two Treatment Design with Quantitative Responses 
In classic jargon, this design falls under the general classification referred to as “n – of – 
1 trial” or Repeated Period Cross-Over design (Senn, 2001). These types of design are 
particularly useful for patients with chronic diseases – like hypertension, cancer, diabetes, 
alzheimer, arthritis, asthma and so on – although it has been known to be useful other purposes 
like examining the short term choice of drugs for osteoarthritis (Yelland et al, 2006). In addition, 
repeated period cross-over designs are necessary for cases where the physician doubts the 
effectiveness of a certain drug on a patient. Generally, the main advantage of repeated period 
cross-over design is that patients act as their own control.  
Assume two treatments denoted T  and C where one could be the control. Also assume 
we have kn  subjects assigned to the thk  sequence. Define kN n=∑ .  Let the thi  subject and 
the thj  period be such that 1,2,3,...i N= and 1,2,3j = . Ratkowsky et al. (1993) compared the 
efficiencies of various 2 treatments and 3 periods design for estimating a mean treatment effect. 
In the pictures below, we present a few of the designs compared.  
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Design 1:                            Period                             Design 2:                  Period 
                                           1      2    3                                                        1      2    3                                                       
               Sequence      
1
2
3
4
  
T C C
C T C
C T T
T C T
                      Sequence       
1
2
3
4
  
T C C
C T T
C C T
T T C
  
 
Design 3:                             Period                                          
                                           1      2    3                                                                             
               Sequence      
1
2
3
4
5
6
  
T T C
T C T
C T T
C C T
C T C
T C C
          
 
They concluded that the most efficient of the three designs – in terms of variability and 
computational difficulties – was Design 2. Using all three designs, we performed some 
superficial analyses of individual treatment effect variability using the potential outcome method. 
Among the three, Design 3 had the advantage of separating time effects from true individual 
treatment effects. So, Design 3 is used for analyses in this chapter. 
The following random assignment of treatment is used, where 6 sequences are grouped 
into 2 squares as shown below. 
          
               
               
           1      2      3
             1
1
    2   
3
Period
Square
T T C
Sequence T C T
C T T
        
                               
                                  
                              1       2     3
 2
1
   2   
3
Period
Square
C C T
Sequence C T C
T C C
                          (R-1) 
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Notice that, for every subject, there are  32 2 6k = − =  different possible assignments of 
the treatments in the three periods. The treatment options, TTT and CCC do not concretely 
capture the cross over design as subjects do not change treatment (parallel design). Initially, we 
will restrict the randomization of treatments to Square 1.  Square 2 is a mirror image of square 1 
with T and C flipped. The analysis will be done under two situations: Unequal and equal number 
of subjects per sequence. 
 
3.1:  Unequal Number of Subjects per Sequence 
Assume the subjects are independently and randomly assigned to the sequences. Note 
that this allows for a possible unequal number of subjects per sequence. Let an indicator random 
variable ijδ  be a sequence assignment variable for the thi subject, thj  period with 
1,2,3,...,i N=  and 1,2,3j = . 
For square 1, define 
                               
1,     if subject  receives  is in period 
0,                                   otherwise           ij
i C jδ = 

 (1.1) 
Thus, (1,1 / 3)ij Binomialδ ∼ .  Thus, ( ) 1 1 / 3ijP δ = =  for all j  and  
}
}
}
1 1 2 3
2 2 1 3
3 3 1 2
    1,  0,  0
    1,  0,  0
    1,  0,  0
i i i i
i i i i
i i i i
CTT or
TCT or
TTC or
δ δ = δ = δ =
δ δ = δ = δ =
δ δ = δ = δ =
 
For each i  and j j′≠ , we have that, ( ) 1/ 3ijEδ δ = , ( ) 0ij ijE ′δ δ δ =  
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( ) ( )
( ) ( )
( )
1,  1
                 1 1
1/9 , if   j
                   
1 / 9, if  j
ij i j ij i j
ij i j
E P
P P
j
i ij
′ ′ ′ ′δ
′ ′
δ δ = δ = δ =
= δ = δ =
′=
′= ≠
′≠
 
and ( ) ( )2ij ijE Eδ δδ = δ . Note, ( )...Eδ  denoted the expectation with respect to the finite 
population randomization. The total number of subjects in the sequences constitutes the size of 
the population.  
We assume no carryover effects. Let ijt  and ijτ denote the unobservable time effects due 
to treatment T and C respectively. ( )1 2 3, ,i i it tt t′ =  and ( )1 2 3, ,i i iτ ττ τ′ =  are periodic effect 
parameters. That is, these parameters quantify the unobservable effects from period to period 
when the same subject is given the same treatment. Let i ijX t+  and Y +i ijτ  be the observed 
responses to T andC respectively. The potential outcomes at time periods 1, 2 and 3 are 
 1 1 2 2 3 3
1 2 3
, Y +   ;  , Y +   ;  , Y +   i i i i i i i i i i i i
P P P
X t X t X t+ τ + τ + τ
    (1.2) 
where P1, P3 and P3 denote the periods . iX  and iY  denote the average response (to treatments T 
and C respectively) over the three periods. For the thi subject we have, 
3
1
0 ij
j
t
=
=∑  and 
3
1
0ij
j=
τ =∑  . 
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These potential treatment outcomes are established under the condition that only one 
measurement of the subject’s response at a particular period is observable. The true individual 
treatment effect on the thi  subject in the thj  period is defined  
ij i i ij ijD X Y t= − + − τ ………………………………………..(#) 
Define, 
3
1
1
3i ijj
D D
=
= ∑ . Thus, 
3 3
1 1
i i i ij ij i i
j j
D X Y t X Y
= =
= − + − τ = −∑ ∑    (since 
3 3
1 1
0 and 0ij ij
j j
t
= =
= τ =∑ ∑ ) 
Note iD  is not observable for any 1,2,...,i N= . The “true” (overall) mean effect of treatment 
D  is given as D X Y= − . That is, 
                                                           
1 1
1 1N N
i i
i i
D X Y
N N
= =
 
= − 
 
∑ ∑    
 
Remark 3.1 
D is the true finite population mean treatment effect of the N  subjects in the study. The 
finite population variance of the true individual treatment effects (denoted 2DS ) is 
( )22
1
1 N
D i
i
S D D
N
=
= −∑ . 
 
Remark 3.2 
2
DS  represents the overall individual treatment response variability or overall subject-by-
treatment interaction.  That is, the variability of subjects’ responses on the same treatment that 
  
 27 
depends on the treatment administered or the extent to which the difference between treatments 
T and C depend on the subject.  
Let id  be the observed treatment effect for the 
thi subject taken over the Square 1 
randomization (R-1). We have that, 
           
( )
( )
( )
1 2
3 3
2 3
1 1
1 3
2 2
                               (for TTC)
2
                                   (for CTT)
2
                     
2
i i i i
i i i i
i i i i
i i i
i i i i
i i i
X t X td Y
X t X t Y
X t X t Y
+ + + 
= − + τ δ 
 
+ + + 
+ − + τ δ 
 
+ + + 
+ − + τ δ 
 
              (for TCT)
 
( ) 3 2 3 1 3 1 21 2 3 1 1 2 2 3 3
1
              
2 2 2
i i i i i i
i i i ij i i i i i i i i i
j
t t t t t td X Y
=
+ + +     
⇒ = − δ + δ + δ + δ −τ δ −τ δ −τ δ     
     
∑
  
Thus,       ( ) 3 3
1 1
  - i i i ij ij ij
j j
d X Y
= =
= − δ α δ∑ ∑  
    
( ) 3
1
  -                                i i i ij ij
j
d X Y
=
= − α δ∑  (1.3) 
where  2
ij
ij ij
t 
α = + τ 
 
  and 
3
1
1ij
j=
δ =∑ . Now, let d be the mean observed effect over all 
subjects. We have that, 
1
1 N
i
i
d d
N
=
= ∑ . We also assume that the observed individual response 
variability, denoted 2dS , is ( )22
1
1
1
N
d i
i
S d d
N
=
= −
−
∑ . 
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Remark 3.3 
2
dS  is the total observed variability that results from subjects given different treatments at 
different periods of time. Hence, 2dS  may be seen as the sum of subject-by-treatment interaction 
and the variability within the subject over time.  
 
Proposition 3.1   
The mean observed treatment effect is an unbiased estimate of the true mean effect.  That is, 
 ( )E d Dδ =  (1.4) 
Proof: 
( ) ( )
1
1 N
i
i
E d E d
Nδ
=
= ∑  
               ( ) 3
1 1
1 N
i i ij ij
i j
X Y
N
= =
 
= − − α δ 
 
∑ ∑                                          
             
( ) ( )3
1 1
1
 
N
i i ij ij
i j
X Y E
N
= =
 
= − − α δ 
 
∑ ∑  
             ( ) 3
1 1
1 1
 
3
N
i i ij
i j
X Y
N
= =
 
= − − α 
 
∑ ∑  
             ( )
1
1
 
N
i j
i
X Y
N
=
= −∑               
3 3
1 1
since 0 and 0ij ij
j j
t
= =
 
= τ = 
 
∑ ∑  
                D=         
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Proposition 3.2 
For each subject, the observe treatment effect variability is not an unbiased estimator of 
the true individual treatment variability. That is, 
2 21
d d IND
NE S S Bias
Nδ
− 
= + 
 
 
Hence, 2dS  is a biased estimate of 
2
DS , where 
3
2
2
1 1
1
3
N
IND ij
i j
NBias
N
= =
−
= α∑∑ , 2
ij
ij ij
t
α = + τ  and 
INDBias  represents the bias for the design where subjects are independently assigned to 
sequences. 
Proof:  See Appendix B 
 
Remark 3.4 
INDBias  involves only time effect parameters and may be thought to quantify variability 
of treatment responses within subject. That is, the variability that results when the same subject 
is given the same treatment at different periods of time. 
 
Corollary 3.1 
Define 2ij ijt = − τ then, from (1.3), i id D= . That is, the observed treatment effect, id ,  is 
same as the true treatment effect, iD ,  but ijD , defined in Equation (#), is not constant across 
periods because, under this condition, 1 13i i i iD X Y= − − τ , 2 23i i i iD X Y= − − τ , 
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3 33i i i iD X Y= − − τ  and each of these depend on the time effect parameter ijτ . Note, again, that 
3
1
1
3i ijj
D D
=
= ∑ . 
A stronger condition exists when ijt  and ijτ  are all equal to zero.  In this case, i id D= , 
2 2
d DS S=  and iD is the same across periods since, in this case, 1 2 3i i i i iD D D X Y= = = − . 
Next, we turn our attention to the second situation in the analyses of individual treatment 
effect variability for quantitative responses: Equal number of subjects per sequence. 
 
3.2:  Equal Number of Subjects Assigned to Sequence  
In the last section, we dealt with a possible case of unequal number of subjects per 
sequence due to the independent assignment of subjects to sequences. Now, assume that the 
randomization must result in equal number of subjects per sequence. Suppose we assign n 
subjects to each sequence, we would have a total of 3N n=  subjects assigned to the three 
sequences under consideration.  
Total Randomization
 
# for seq3#  for seq1 #  for seq2
n
 
n
N N n
nn
−     
=      
     
 
Furthermore, ( )1/ 3ij Bernoulliδ ∼ .  Thus, ( ) 1 1 / 3ijP δ = =  for all j  and  
 
3N n=
   
}
}
}
1 1 2 3
2 2 1 3
3 3 1 2
    1,  0,  0
    1,  0,  0
    1,  0,  0
i
i
i
CTT or
TCT or
TTC or
δ δ = δ = δ =
δ δ = δ = δ =
δ δ = δ = δ =
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For the thi  subject, ( ) 1/ 3ijEδ δ = , 2( ) ( )ij ijE Eδ δδ = δ  and ( ) 0ij ijE ′δ δ δ =  (for j j′≠ ).  
Now, for ( )i i′≠ , ( ) ( 1,  1)ij i j ij i jE P′ ′ ′ ′δ δ δ = δ = δ =  
                                       
( 1| 1) ( 1)ij i j i jP P′ ′ ′ ′= δ = δ = δ =  
                 
1 1
                   for j = j
1 3
    
1
                   for j j
1 3
n
N
n
N
− 
′ 
− 
= 
  ′≠ 
− 
 
 
Proposition 3.3 
For each subject, the observe treatment effect variability is not an unbiased estimator of 
the true individual treatment variability. That is,  
2 21
d D DEP
NE S S Bias
Nδ
− 
= + 
 
 (1.5) 
Thus, 2dS  is not an unbiased estimate of 
2
DS   where    
3 3 3 3
2
2
1 1 1 1 1 1 1 1 1
( )  ( )
1 1( 1)
1 13
N N N N N
DEP ij ij i j ij i j
i j i i j i i j j
i i i i and j j
n nBias N
N NN ′ ′ ′′ ′ ′= = = = = = = = =
′ ′ ′≠ ≠ ≠
 
 
−
 = − α − α α − α α
− − 
 
 
∑∑ ∑∑∑ ∑∑∑∑
 
 
where 
2
ij
ij ij
t
α τ
 
= + 
 
 and DEPBias  represents the bias for the design where the assignment of 
the next subject to a sequence depends on the previous subject’s assignment.  
Proof:  See Appendix C                                    
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 Corollary 3.2 
  If 2ij ijt = − τ , the conditions in corollary 3.1 also apply here. In general, the observed 
treatment effect variability is biased for the true treatment effect variability.  
 
3.3:  Parameter Estimation 
To proceed further with the estimation of the individual treatment effect variability, we 
use a population of time effects. We make the following assumptions. Let 1 2 3, , )( i i it t tt′ =  and 
1 2 3, , )( i i iτ τ ττ′ = , for 1,2,...,  and 1,2,3.i n j= =  Assume 1
2
 
i
i
t
t
 
 
 
and 1
2
i
i
 
 
 
τ
τ
 are independent and 
identically distributed (i.i.d.) 1 2
2
1
1
t
t
t
ρ µ   
σ    ρµ    
 and 3 2
4
1
1
τ
τ
τ
ρ µ   
σ    ρµ    
, respectively. Also 
assume, 
1
2
 
i
i
t
t
 
 
 
and 1
2
i
i
 
 
 
τ
τ
 are jointly independent. We note that ( )3 1 2i i it t t= − +  and 
( )3 1 2i i iτ = − τ + τ . Estimates of the distribution parameters will be derived. 
The variables 1 2 3, ,i i it t t  or 1 2 3, ,i i iτ τ τ  cannot be observed separately. However, certain 
combinations of 1 2 3, , )( i i it t tt′ =  or 1 2 3, , )( i i iτ τ ττ′ =  can be used as estimates of the effect 
parameters. That is, from the combination TTC , we can observe 1 2( )i it t− . Similarly, from the 
data in sequences TCT and CTT, we can observe ( )1 3i it t−  and ( )2 3i it t− , respectively. Upon 
substituting for 3it , they simplify to 1 2( )i it t− , ( )1 22 i it t+ and ( )1 22i it t+  respectively. The 
matrix  
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1 2
1
1 2
2
1 2
1 1
2 1 2
2 2 1
i i
i
i i
i
i i
t t
t
M t t
t
t t
− −   
    
= + =     
    +   
  contains only two linear combinations that are linearly 
independent so one can make use of any two of  1 2( )i it t− , ( )1 22i it t+ and ( )1 22 i it t+ . 
Correspondingly, from the data in Square 2 of (R-1), we can observe 1 2( )i iτ − τ , ( )1 22i iτ + τ and 
( )1 22 i iτ + τ . Henceforth, we will omit the “ i ” in expressions like 1 2( )i it t− , 1 2( )i iτ − τ  etc. 
Thus, we have that, 
1 2 1 2( )E t t µ µ− = −  (1.6) 
1 2 1 2( 2 ) 2E t t+ = µ + µ  (1.7) 
1 2 1 2(2 ) 2E t t+ = µ + µ  (1.8) 
where the expectation is taken with respect to the population of time effects given above. Using 
the above equations, we propose the estimates, 1µˆ  and 2µˆ , corresponding to the population 
means, 1µ  and 2µ , as 1 1 2 1 2
1
ˆ 2( ) ( 2 )
3
t t t t µ = − + +   and  2 1 2 1 2
1
ˆ ( 2 ) ( )
3
t t t t µ = + − −  . 
Similarly we have, ( )3 1 2 1 21ˆ 2 ( 2 )3  µ = τ − τ + τ + τ   and 4 1 2 1 21ˆ ( 2 ) ( )3  µ = τ + τ − τ − τ  , where 
1 2t t−  and 1 22t t+ , are the means of the observed differences between responses from subjects 
who received treatment T in sequences TTC  and CTT , respectively. Similarly, 1 2τ − τ  and 
1 22τ + τ  are the means for those who received treatment C  in sequences CCT and TCC ,  
respectively. 
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Let  2 2 2 21 2 3 4,  ,  ,  S S S S  be the sample variances of 1 2t t− , 1 22t t+ , 1 2τ − τ  and 1 22τ + τ  
respectively. We observe that, 21 1 2( ) ( )E S Var t t= −  and 22 1 2( ) ( 2 )E S Var t t= + . Similarly, 
2
3 1 2( ) ( )E S Var= τ − τ  and 24 1 2( ) ( 2 )E S Var= τ + τ .  
 
Proposition 3.4 
Let 1 2i i iu t t= −  or simply 1 2u t t= −  and 1 22v t t= + . Assume  1 2, ,...u u   and 1 2, ,...v v  
are . .i i d  with finite fourth moments. Define 2 2 21 2
1
ˆ 2
9t
S S σ = +   and  
2 2 2
3 4
1
ˆ 2
9
S Sτ  σ = +  . 
Then, 2ˆ tσ  and 
2
ˆ τσ are unbiased and consistent estimates of 
2
tσ  and 
2
τσ respectively.  
Proof: 
We will show the proof for the formulas involving t . Those with τ  follow in the same manner. 
2
1 1 2( ) ( )E S Var t t= −  
            
2
1 22 2 ( , )t Cov t t= σ −                                                                                     (1.9) 
2
2 1 2( ) ( 2 )E S Var t t= +  
           
2
1 25 4 ( , )t Cov t t= σ +                                                                                    (1.10) 
Hence, by elimination, 
2 2 2
1 2
1 2 ( ) ( )
9t
E S E S σ = +  .  
Similarly, we obtain 2 2 23 4
1 2
9
S Sτ  σ = +  .  Define 
2 2 2
1 2
1
ˆ 2
9t
S S σ = +   and  
2 2 2
3 4
1
ˆ 2
9
S Sτ  σ = +  , 
we have that,                                                        
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( ) ( ) ( )
[ ]
( ) ( )
2 2 2
1 2
1 2 1 2
2 2
1 2 1 2
2
1
ˆ 2
9
1
          2 ( ) ( 2 )
9
1
          2 2 2 ( , ) 5 4 ( , )
9
          
t
t t
t
E E S E S
Var t t Var t t
Cov t t Cov t t
 σ = + 
= − + +
 = σ − + σ + 
= σ
 
Hence, 2ˆ tσ
 
is an unbiased estimate of 2tσ . Similarly, we can show that 
2
ˆ τσ  is unbiased for 
2
τσ . 
Consistency:  Since the fourth moments exists, by using two applications of the weak law of 
large numbers and the continuous mapping theorem, we have that, 
( ) ( )( ) ( )22 2 2 21 1 1 1
1
1 1 var
1
N
P
i N
i
NS u u E u E u u
N N
=
 
= − → − = 
−  
∑ . 
Thus, ( )21 1 2PS Var t t→ − .  
Similarly, ( )22 1 22PS Var t t→ + .  Hence, ( ) ( ) ( )( )2 21 2 1 2 1 2, , 2PS S Var t t Var t t→ − + .  
Now, let ( )2 2 21 2ˆ ,t g S Sσ = . Also, let, 2 2:g →   be continuous at every point on a set G such 
that, ( )( )2 21 2, 1P S S G∈ = . Further applications of continuous mapping theorem and Slutsky 
theorem leads to  
( ) ( ) ( )2 2 2 21 2 1 2 1 21ˆ , 2 29Pt tg S S Var t t Var t tσ = → − + + = σ   . That is 2 2ˆ Pt tσ →σ . Hence, 
2
ˆ tσ  is a consistent estimator of 
2
tσ .  Similar proof for 
2
ˆ τσ  can be established.                               
 
Corollary 3.3 
From proposition 3.4, we may define estimates of the true correlation values tρ and τρ as  
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2 2
2 1
2 2
2 1
1 2 5
ˆ
2 2t
S S
S S
 
−ρ =  
+ 
 and 
2 2
4 3
2 2
4 3
2 51
ˆ
2 2
S S
S Sτ
 
−ρ =  
+ 
. We propose that ˆ tρ and ˆ τρ  are consistent 
estimates of tρ and τρ respectively. 
Proof: 
Using equations (1.8) and (1.9), we have that 
2 2
1 2 1
1( , ) ( )
2t
Cov t t E S= σ −  
    ( )2 22 11 2 ( ) 5 ( )18 E S E S= −  
after substituting 2tσ  from above. Hence,  
1 2
1 2
( , )
( ) ( )t
Cov t t
Var t Var t
ρ =  = 
2 2
2 1
2 2
2 1
1 2 ( ) 5 ( )
2 ( ) 2 ( )
E S E S
E S E S
 
−
 + 
 
Define 
2 2
2 1
2 2
2 1
1 2 5
ˆ
2 2t
S S
S S
 
−ρ =  
+ 
 and 
2 2
4 3
2 2
4 3
2 51
ˆ
2 2
S S
S Sτ
 
−ρ =  
+ 
. From Proposition 3.4, 
( )22 1 22PS Var t t→ + .  Hence, ( ) ( ) ( )( )2 21 2 1 2 1 2, , 2PS S Var t t Var t t→ − + .  Assume 
( )2 21 2ˆ ,t h S Sρ = . Let, 2 2:h →   be continuous at every point on a set H such that, 
( )( )2 21 2, 1P S S ∈Η = .  Further applications of continuous mapping theorem and Slutsky 
theorem, gives  
( ) ( ) ( )( ) ( )
2 2
2 2 1 2 1 22 1
1 2 2 2
1 2 1 22 1
2 2 51 2 5 1
ˆ ,
2 2 2 22
P
t t
Var t t Var t tS Sh S S
Var t t Var t tS S
   + − −
−ρ = = → = ρ    + + −+   
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Thus,  ˆ Pt tρ →ρ  and ˆtρ  is a consistent estimator of tρ . The proof for ˆτρ follows in a similar 
manner.                                                                                                                                             
 
3.4:  Expected Bias Estimation 
Now find estimates for the bias factor developed in the previous sections are found under 
various situations. 
 
3.4.1:  Bias Estimation for the Case of Unequal Subjects per Sequence 
First consider the case for the bias under the independent assignment of subjects which 
was given as   
3
2
2
1 1
1
3
N
IND ij
i j
NBias
N
= =
−
= α∑∑  
where   
2
ij
ij ij
t 
α = + τ 
 
 and 1,2,3,...,i N=  is the total number of subjects in the sequences. 
 
Proposition 3.5 
Given the 1
2
 
t
t
 
 
 
and 1
2
 
 
 
τ
τ
 are independent and identically distributed 1 2
2
1
1
t
t
t
ρ µ   
σ    ρµ    
 
and 3 2
4
1
1
τ
τ
τ
ρ µ   
σ    ρµ    
, respectively,  and assuming 1
2
 
t
t
 
 
 
and 1
2
 
 
 
τ
τ
 are jointly independent, we 
propose that, 
  
 38 
1( )
6IND
NE Bias Q
N
−
=  
where expectation is taken over the distribution of 1
2
 
t
t
 
 
 
and 1
2
 
 
 
τ
τ
 and  
( ) ( ) ( ) ( )
( )( )( )
222 2
1 2 1 2 3 4 3 4
1 2 3 4 1 4 2 3
2 4 2 4 4
      2
t tQ τ τ= + ρ σ + + ρ σ + µ + µ − µ µ + µ + µ − µ µ
+ µ + µ µ + µ + µ µ + µ µ
 
Proof: 
( )
23
2
1 1
1
23
N
ij
IND ij
i j
tNE Bias E
N
= =
 
−
= + τ 
 
∑∑ . 
But,     ( ) ( )
2 23 3 3 3
2
1 1 1 12 4
j j
j j j j
j j j j
t t
E E E E t
= = = =
  
+ τ = + τ + τ       
∑ ∑ ∑ ∑           
                       ( ) ( ) ( ) ( )2 22 2 22 23 3 3 3
1 1 14 4
j
j j j
j j j
t tE E E E E t E t
= = =
   
= + + τ + τ + τ + τ       
∑ ∑ ∑  
Now,  ( )3 3 1 2
1
0j
j
t t t t
=
= ⇒ = − +∑  and ( )
3
3 1 2
1
0j
j=
τ = ⇒ τ = − τ + τ∑ . Thus, 
( ) ( ) ( ) ( ) ( )( )( )
2 23 2 2 22 22
1 2 1 2 1 2 1 2
1 1 1 1
1
2 4 4
j j
j j j j
j j j j
t t
E E E t t E E E t E t t
= = = =
  
+τ = + + + τ + τ +τ + τ + + τ +τ       
∑ ∑ ∑ ∑  
                        
( ) ( ) ( ) ( ) ( ) ( )
( ) ( ) ( ) ( ) ( )
2 2 22 2 2 2
2 1 2 1 21
1 1
2
1 1 1 2 2 1 2 2
1
1 1 1 1
4 4 4 2
  
j j
j j
j j
j
E t E t E t E t t E E
E t E t E t E t E t
= =
=
= + + + + τ + τ + τ
+ τ + τ + τ + τ + τ
∑ ∑
∑
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From Section 3.3, ( )2 2 211  tE t = σ + µ and ( ) ( ) 21 2 1 2 1 2 1 2, t tE t t Cov t t= + µ µ = ρ σ + µ µ . In 
addition, ( ) ( ) ( ) ( )1 1 1 1 1 1 1 3,E t Cov t E t Eτ = τ + τ = µ µ  (τ ’s and t ’s jointly independent) - this 
relationship applies to other expectations in the formula above. Thus, 
( ) ( ) ( )
( ) ( ) ( )
( )
23
2 2 2 2 2
1 2 1 2
1
2 2 2 2 2
3 4 3 4
1 3 2 4 1 4 2 3
2 2 1
 
2 4 4 2
                         2 2 2
                         2
j
j t t t t
j
t
E
=
τ τ τ τ
 
+ τ = σ + µ + σ + µ + ρ σ + µ µ 
 
+ σ + µ + σ + µ + ρ σ + µ µ
+ µ µ + µ µ + µ µ + µ µ
∑
 
                
( ) ( ) ( ) ( )
( )( )( )
222 2
1 2 1 2 3 4
3 4 1 2 3 4 1 4 2 3
1 2 4 2 4
2
       4 2
t t τ τ
= + ρ σ + + ρ σ + µ + µ − µ µ + µ + µ


− µ µ + µ + µ µ + µ + µ µ + µ µ 
  
                
1
2
Q=                                                                                             (1.11) 
where,  
( ) ( ) ( ) ( )
( )( )( )
222 2
1 2 1 2 3 4
3 4 1 2 3 4 1 4 2 3
2 4 2 4
      4 2
t tQ τ τ= + ρ σ + + ρ σ + µ + µ − µ µ + µ + µ
− µ µ + µ + µ µ + µ + µ µ + µ µ
 
We then have, 
     ( )
23
2
1 1
1
23
N
ij
IND ij
i j
tNE Bias E
N
= =
 
−
= + τ 
 
∑∑  
( ) 2
1
1 1
23
N
IND
i
NE Bias Q
N
=
−
⇒ = ∑  
               
1
6
N Q
N
−
=                                                   
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Next, the analyses are continued with the bias estimation for the case where the randomization 
should result in equal number of subjects per sequence. 
 
3.4.2:  Bias Estimation for the Case of Equal Number of Subjects per Sequence 
Consider finding the estimate of the expectation of the second bias.  From proposition 
3.3, the bias is given as 
( ) 3 3 3 322
1 1 1 1 1 1 1 1 1
( )  ( )
1 11
1 13
N N N N N
DEP ij ij i j ij i j
i j i i j i i j j
i i i i and j j
n nBias N
N NN ′ ′ ′ ′′ ′ ′= = = = = = = = =
′ ′ ′≠ ≠ ≠
 
 
−
 = − α − α α − α α
− − 
 
 
∑∑ ∑∑∑ ∑∑∑∑
 
 
where 
2
ij
ij ij
t 
α = + τ 
 
 and 3N n=  is the total number of subjects in the three sequences with n  
subjects each. 
 
 
Proposition 3.6 
Given the 1
2
 
t
t
 
 
 
and 1
2
 
 
 
τ
τ
 are independent and identically distributed 1 2
2
1
1
t
t
t
ρ µ   
σ    ρµ    
 
and 3 2
4
1
1
τ
τ
τ
ρ µ   
σ    ρµ    
, respectively,  and assuming 1
2
 
t
t
 
 
 
 and 1
2
 
 
 
τ
τ
 are jointly independent, 
we propose that, 
1( )
6DEP
E Bias Q=  
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where expectation is taken over the distribution of 1
2
 
t
t
 
 
 
and 1
2
 
 
 
τ
τ
 and  
( ) ( ) ( ) ( )
( )( )( )
222 2
1 2 1 2 3 4
3 4 1 2 3 4 1 4 2 3
2 4 2 4
      4 2
t tQ τ τ= + ρ σ + + ρ σ + µ + µ − µ µ + µ + µ
− µ µ + µ + µ µ + µ + µ µ + µ µ
   
Proof: 
Let’s define the following quantities as 
3
2
1 1
N
ij
i j
U
= =
= α∑∑ , 
3
1 1 1
N N
ij i j
i i j
i i
V
′
′= = =
′≠
= α α∑∑∑

 and  
3 3
1 1 1 1
( )  ( )
N N
ij i j
i i j j
i i and j j
W
′ ′
′ ′= = = =
′ ′≠ ≠
= α α∑∑∑∑

 
( ) ( ) ( ) ( )21 1( ) 1 1 13DEP
n nE Bias N E U E V E W
N NN
− 
= − − − 
− − 
                                   (1.12) 
where expectation is taken over the distribution of 1
2
 
t
t
 
 
 
and 1
2
 
 
 
τ
τ
.  Next, we find the expectation 
of each quantity in the bias statement. Hence,   
( )
23
1 1 2
N
ij
ij
i j
t
E U E
= =
 
= + τ 
 
∑∑ 2
N Q=                                                                                        (1.13)       
( ) ( )3
1 1 1
N N
ij i j
i i j
i i
E V E
′
′= = =
′≠
= α α∑∑∑

 
           
23
1 1 1 2
N N
ij
ij
i i j
i i
t
E
′= = =
′≠
 
= + τ 
 
∑∑∑

         (since i  and i′  have the same distribution) 
           
1 1
1
2
N N
i i
i i
Q
′= =
′≠
=∑∑

,     
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( )1
2
N N Q−=                                                                                                             (1.14) 
Finally, 
( ) 3 3
1 1 1 1
( )   ( )
N N
ij i j
i i j j
i i and j j
E W E
′ ′
′ ′= = = =
′ ′≠ ≠
= α α∑∑∑∑

 
3 3
1 1 1 1
( )
( )
N N
ij i j
i i j j
j j
i i
E
′ ′
′ ′= = = =
′≠
′≠
 
 
 = α α
 
 
 
∑∑ ∑∑


 
23 3
1 1 1 1
( )
N N
ij ij i j
i i j j
i i
E
′
′= = = =
′≠
  
 = α − α α 
   
∑∑ ∑ ∑

            
23 3 3 3
1 1 1 1
( )
since ij i j ij ij i j
j j j j
j j
′ ′ ′
′= = = =
′≠
 
  
 α α = α − α α 
  
 
 
∑∑ ∑ ∑

 
3
1 1 1
( ) 
N N
ij i j
i i j
i i
E
′
′= = =
′≠
= − α α∑∑∑

            
3
1
since 0ij
j=
 
= 
 
 
∑α  
 ( ) ( )1
2
N N
E V Q−= − = −                                                                                        (1.15) 
Putting (1.13), (1.14) and (1.15) into (1.12) gives 
( ) ( ) ( )
2
1 1 11 1 1( )
2 1 2 1 2 63DEP
N N N N N Nn nE Bias Q Q Q Q
N NN
− − − 
−
= − + = 
− − 
           
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Remark 3.6 
From the estimated expected bias formulas above, we observe that 
( ) ( )IND DEPE Bias E Bias≤  for all n values. In addition,  
( ) ( )IND DEPNLimE Bias E Bias→∞ =  because 
1 1
6 6N
NLim Q Q
N→∞
− 
= 
 
 since  1 1
 as N
6 6
N
N
−
→ →∞ . 
 
Earlier, we saw that, the true individual treatment effect variability, 2DS , cannot be 
measured. Furthermore, the observed treatment effect variability is not unbiased for 2DS .  
However, having established the formulas for the expected bias in both situations, in the next 
section, we propose an estimate the true individual treatment effect variability.  
 
3.5:  Estimate of the True Individual Treatment Response Variability 
Consider the case when the subject assignment to treatment is independent. We had that, 
2 21
d D IND
NE S S Bias
Nδ
− 
= + 
 
. Thus, ( )2 21D d INDNS E S BiasN δ−= −  . An estimate of 2DS , 
denoted 2ˆDS ,  is given as 
2 21 1
ˆ ˆ
6D d
N NS S Q
N N
− −
= −  
where 2dS  is the observed individual treatment response variance and  
( ) ( ) ( ) ( )
( )( )( )
222 2
1 2 1 2 3 4 3 4
1 2 3 4 1 4 2 3
ˆ
ˆ ˆˆ ˆ ˆ ˆ ˆ ˆ ˆ ˆ ˆ ˆ2 4 2 4 4
ˆ ˆ ˆ ˆ ˆ ˆ ˆ ˆ
     2
t tQ τ τ= + ρ σ + + ρ σ + µ + µ − µ µ + µ + µ − µ µ
+ µ + µ µ + µ + µ µ + µ µ
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Remark 3.7 
An estimate for the case of equal number of subjects per sequence is given as 
2 21 1
ˆ ˆ
6D d
NS S Q
N
−
= −  
where      
( ) ( ) ( ) ( )
( )( )( )
222 2
1 2 1 2 3 4 3 4
1 2 3 4 1 4 2 3
ˆ
ˆ ˆˆ ˆ ˆ ˆ ˆ ˆ ˆ ˆ ˆ ˆ2 4 2 4 4
ˆ ˆ ˆ ˆ ˆ ˆ ˆ ˆ
     2
t tQ τ τ= + ρ σ + + ρ σ + µ + µ − µ µ + µ + µ − µ µ
+ µ + µ µ + µ + µ µ + µ µ
 
In the next, we compare the estimated values with the actual parameters in an illustrated 
example.  The illustrated example puts a normal distribution to the second population type stated 
above. That is, time effect parameters are given a bivariate normal distribution.  
 
3.5.1:  Illustrative Example 1: Estimating the Bias Term 
As an example to compare the actual parameter values with the estimated values, we 
simulated two bivariate normal data of 1
2
 
t
t
 
 
 
and 1
2
 
 
 
τ
τ
. Assume  
1
2
5.667 31.333 6.667
 
7.333 6.667 31.333
iidt
N
t
−      
      
− −      
∼  giving 0.213tρ = −  and 
1
2
0.667 7.333 6.167
  
1.333 6.167 7.333
iid
N
τ −      
      τ − −      
∼  producing 0.841τρ = − . The parameter values were 
taken from a previous simulation work on randomization and they are considered known.  1000 
estimates (using the formulas above) were calculated from simulated data sets consisting of 300 
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     Table 3.1: Comparing True Values and Values from Estimators using 1000 simulated data of    size 
300 
Population Parameter         True Pop. Value *Estimated Mean *Estimated Std dev. 
Mean of 1t                    5.667 5.663 0.387 
Mean of 2t                    -7.333 -7.335 0.272 
Mean of 1τ                   0.667 0.668 0.205 
Mean of 2τ                   -1.333 -1.334 0.113 
Variance of t                31.333 31.340 1.820 
Variance of τ               7.333 7.333 0.507 
Covariance ( )1 2,t t        -6.667 -6.646 2.134 
Covariance ( )1 2,τ τ       -6.167 -6.162 0.630 
Correlation ( )1 2,t t        -0.213 -0.211 0.066 
Correlation ( )1 2,τ τ       -0.841 -0.839 0.039 
Expected bias – Indep. 28.191 28.270 1.602 
Expected bias – Dep. 28.163 28.300 1.604 
     *Estimated mean is the mean of 1000 estimates obtained from simulated data with 300 subjects per sequence.  
      *Estimated Stdev. is standard  deviation of 1000 estimates obtained from simulated data. 
 
Notice the closeness between the estimates and the actual values. In addition, the 
standard errors of the estimates are small. The graphs below further explore the estimated bias 
(for the case of equal subjects per sequence) with increasing sample sizes. Increasing the sample 
size reduces the difference.  
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Figure 3.1: Graph of estimated bias for various sample sizes 
 
Figure 3.2: Graph showing the variance of the estimated bias for various sample sizes 
 
We note that, for increasing sample sizes, the estimated bias approaches the true bias 
value (a). In addition, the variance of the estimated bias approaches zero with increasing sample 
size (b). This illustrates consistency of the bias estimator.   
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Recall that, we analyzed Squares 1 and 2 sequences separately. In the following Section 
3.6, we combine the two analyses and propose an estimate of the overall true individual 
treatment effect variability, which, as expected, consists of the estimates from Squares 1 and 2.  
A note on symbols used here: Estimates with subscripts “1” indicate that they were derived using 
Square 1 sequences; likewise, those with subscripts “2” were are derived using Square 2 
sequences. The estimates from the combined sequences have subscripts “12.” 
 
3.6:  Generalization to all Six Sequences 
It is important to note that, up to this point, we focused on just the three sequences of 
Square 1. Let 1N , 2N , 1D , 2D , 
2
1D
S and 2
2D
S denote: the sample sizes, the true finite population 
mean effects and variances of the effects from Squares 1 and 2, respectively. Let 2
12D
S denote the 
true individual treatment effect variability from the two Squares, we have that, 
1
1
11
1 N
i
i
D D
N
=
= ∑ , 
2
2
12
1 N
i
i
D D
N
=
= ∑ . We define ( )
21 2
2
1212
11 2
1 N N
D i
i
S D D
N N
+
=
 
= − 
+   
∑  where  
( )1 212 1 1 2 2
11 2 1 2
1 1N N
i
i
D D N D N D
N N N N
+
=
= = +
+ +
∑ .  Hence, we have  
( )22 2 2 2 21 2 1 1 2 2 1 1 2 212 1 2
1 2 1 2
1 1
D D DS N S N S N D N D N D N DN N N N
 
= + + + − + + + 
 
We state the plug-in estimate of 2
12D
S  as, 
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( )22 2 2 2 21 2 1 1 2 2 1 1 2 212 1 2
1 2 1 2
1 1
ˆ ˆ ˆ
D D DS N S N S N d N d N d N dN N N N
 
= + + + − + + + 
                  (1.16) 
 
If 1 2 12N N N= =  then ( )
12
2 12
12 1 2
1
1 1
2 2
N
i
i
D D D D
N
=
= = +∑ , ( )12 1 212d d d= +  
( ) ( )22 2 2 1 212 1 21 12 2D D DS S S D D = + + −    and ( ) ( )
22 2 2
1 212 1 2
1 1
ˆ ˆ ˆ
2 2D D D
S S S d d = + + −  
 
 
3.7:   Illustrative Example 2: Simulated Blood Pressure Dataset  
The following example is based on equal number of subjects per sequence. Blood 
pressure (a.k.a. arterial pressure) is the force of circulating blood on the walls of blood vessel. 
Blood pressure is one of the four vital signs sensitive to periodic changes and large individual 
variations. The other three are body temperature, pulse or heart rate and respiratory rate. Blood 
pressure can be systolic or diastolic in nature.  For healthy, resting human adults, normal blood 
pressure ranges from a systolic level less than120mmHg (millimeter mercury) to a diastolic level 
less than 80mmHg, often written as 120/80mmHg. In this example, we simulate blood pressure 
(BP in mmHg) data for 1800 patients who received two treatments T and C for high blood 
pressure related disease at different time periods. The BP values are assumed to come from a 
normal distribution. 300 subjects as randomly assigned to each of the six sequences. The Table 
3.2 below shows the result of the randomization reported in the potential outcome format. All 
values are in millimeters mercury (mmHg). The light grey shaded cells show the observed values 
following assignment to the three sequences in Square 1. 
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This example brings into focus our third population: A super – population distribution of 
treatment effects. Initially, we generate bivariate normal blood pressure responses ( ),X Y  to two 
treatments T and C. In addition, we simulated a bivariate normal time effects under three 
different time periods, the third being determined by the other two. Both treatment responses 
were simulated for each of the three periods. Hence, it was possible to compute the actual 
parameter values and compare with estimates derived using the observed data in Squares 1 and 
2. Section 3.7.1 below details the simulated example. 
 
3.7.1:  Detailed Distributional Specifications for Blood Pressure Date 
In this section, we provide the details of the distributional assumptions that produced the 
blood pressure data, summarized on Table 3.2. The distributions used here illustrate the list of 
distributions mentioned in Section 1.4.  
First, we assumed a pair of blood pressure treatment response variables ( ),X Y  have an 
independent and identically distributed bivariate normal distribution with means 
100X mmHgµ =  and 90Y mmHgµ = , variances 2 29X mmHgσ =  and 2 25Y mmHgσ = , 
respectively. Let ( ), 2Cov X Y = . That is, 100 9 2 
90 2 5
iidX
N
Y
      
      
      
∼ . From the 
distribution of ( ),X Y , we define a “super-population” distribution of individual treatment 
effects D X Y= −  with parameters ( )D E X Yµ = −  and ( )2D Var X Yσ = − . That is, 
( ). . 10,10i i dD N∼ .   
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Second, from the super-population, we draw a finite random sample of 1800 values with 
finite population mean 9.88D mmHg=  and finite population variance 2 210.62DS mmHg= . We 
note that, the quantitative section of this dissertation in centered on estimating 2DS .  
 Third, we let the time effects be distributed as such: 1
2
5 8 1
 
7 1 8
iidt
N
t
      
      
      
∼  and 
1
2
1 5 1
  
2 1 5
iid
N
τ       
      τ       
∼ . Using the values of ( ),X Y  and the time effects, we found the 
potential outcomes for 1800 subjects and the observed outcomes when 300 subjects are assigned 
to each of the six sequences in Squares 1 and 2. The resulting data for Squares 1 is shown on 
Table 3.2 below. 
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Table 3.2: Simulated data of Blood Pressure (BP in mmHg) for 900 subjects with 300 per sequence. The 
light- grey shaded cells are observed data values for corresponding to the sequences. 
 Time Period 1 Time Period 2 Time Period 3 
1x t+  1y τ+  2x t+  2y τ+  3x t+  3y τ+   
Square Seq. Subject 
      
1 109 92 103 89 85 79 
2 97 89 101 87 88 88 
3 98 90 105 90 86 90 
 * * * * * * * 
TTC * * * * * * * 
298 103 87 100 89 101 83 
 299 99 93 108 91 104 92 
Square 1 
 
300 106 92 109 92 99 83 
301 101 89 104 91 85 92 
302 106 89 110 90 90 83 
303 110 93 110 91 83 89 
 * * * * * * * 
TCT * * * * * * * 
598 98 94 105 93 86 83 
599 107 85 105 84 96 92  
600 108 89 113 94 82 90 
601 110 90 113 93 89 88 
602 103 85 108 88 94 90 
603 106 91 107 95 83 77 
 * * * * * * * 
CTT * * * * * * * 
898 106 90 107 95 87 81 
899 107 92 108 88 85 84 
 
 
900 103 88 101 88 98 94 
 
Using the potential outcome method, the true finite population average 
is 1 9.796mmHgD = with point estimate of 1 9.82mmHgd =  for Square 1 data. For the 
randomizations in Square 2, the true finite population mean is 2 9.958mmHgD = with estimate 
given as 2 9.871mmHgd = .  For the combined dataset of six sequences, the true finite 
population average is 12 9.88mmHgD = with point estimate of 12 9.85mmHgd = .  These 
  
 52 
estimates give the average increase in blood pressure due to treatment T relative to treatment C. 
These are the finite population mean estimates upon which decisions about the treatment efficacy 
are sometimes based with less consideration of the individual treatment response effect 
variability. Furthermore, the true standard deviation of the individual treatment effect for the BP 
data and its estimate are
12
3.258mmHg DS = and 12ˆ 3.692mmHgDS = , respectively. The 
estimated coefficient of variation is 0.375 compared to the actual value of 0.330 for the final 
population. The coefficient of variation represents the proportion of the mean treatment effect to 
the standard deviation of the effects. 
The overall actual finite population mean effect, 12 9.88mmHgD = , is positive and the 
standard deviation is a 37.482% “fraction” of the mean.  If it is important that the treatment 
produces a positive effect for most subjects, then the fraction should be small; otherwise the 
fraction could be bigger in favor of applying the treatment to a large population (Longford, 
1999). 
 
3.8:  A Probability of Negative treatment effect 
Let P
−
 denote the probability that a subject will experience a “negative” individual 
treatment effect. Suppose the focus is on the effect of treatment T say, then, negative treatment 
effect means D X Y= − < λ , where 0λ ≥  is a threshold value.  That is, for those individual, C 
is more effective relative to T. Assume that D  has a normal distribution with mean Dµ  and 
variance 2
D
σ . Note that the distribution of D  is determined by the distribution of response 
variables X  and Y which, in this case, are assumed normal.  
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Estimate P
−
 as 
( )
     = 
    
D
D
D
D
D
P P D
P Z
−
= < λ
 λ − µ
< 
σ 
 λ − µ
= Φ  
σ 
 
where D
D
 λ − µΦ  
σ 
 is the cumulative standard normal distribution function evaluated at 
D
D
λ − µ
σ
. Assuming the finite population is large and representative enough, we use the finite 
population mean, 12d ,  and variance, 12ˆDS , as estimates of Dµ  and 
2
D
σ , respectively. That is, 
12 12
ˆ
ˆ ˆ
 and D D Dd Sµ = σ = . Thus, we estimate P−  by 12
12
ˆ
ˆ
D
dP
S−
 λ −
= Φ  
 
 
.  
 
3.8.1:  Illustrative Example 3: Probability of Negative Effect  
Continuing with the analysis of the blood pressure data with 0,λ =  suppose we wish to 
estimate the probability that the true effect of T is less effective in treating hypertension than that 
of C , that is, ( ) ( )0P X Y P D< = < . Using the potential treatment method, the estimated 
probability is given as 
( ) ( )0 9.850 2.67 0.0038
3.692
P P D
Λ
−
− 
= < = Φ = Φ − = 
 
	
, where 0,λ = 12ˆ 9.85 D dµ = = and 
12
ˆ
ˆ 3.692D DSσ = = . Thus, a randomly selected individual has an estimated probability of 0.0038 
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of being better off on treatment C relative to treatment T. C is estimated to be more effective 
than T for at most 0.38% of the population. If there is a tolerance or threshold probability level, 
we may then decide whether of not T is superior to C. 
 
3.9: Repeated Measure Analyses and Potential Outcome Method 
The Grizzle (1965, 1974) model for two treatments - two periods crossover design could 
be extended to higher design. Here we extend it to the 2 treatments, 3 periods crossover design 
without carryover. With  more than one subject per sequence, the general model for the treatment 
response variable Y  with random subjects within sequence specification – modified form of 
Cross-Over Experiment by Ratkowski et al. (1993, page 60)  and Jones and Kenward (1989) – 
can be written as 
 ( ) ( )ijk j t it ijki ky S= µ + η + pi + θ + θ + ε                                                 (1.17) 
with  
( )ijk ij j tE y = µ = µ + pi + θ  
where, 
ijky  is the observed response for the 
thi  subject in the thj period of the thk sequence 
ijµ  is the true mean response for the thi  subject in the thj period  
µ  =  an overall mean effect 
( )i kη =  the random effect due to the 
thi  subject in the  thk sequence; 1,2,3,...,6k = ; 
1,2,3,..., ki n= , kn  being the number of subjects per sequence  
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jpi =  the period effect, 1,2,3j =  
tθ =  the effect of treatment t  
( )itηθ =  the random effect of interaction between the thi  subject and the tht  treatment. 
ijkε = the random experimental error effect of the 
thi  subject in period j  of sequence thk . 
Assume ( ) ( )20, si k iid Nη σ∼ , ( )2( ) 0,it siid N θηθ σ∼  and ( )20,ijk wiid Nε σ∼ . Observed 
values at the different periods and sequences (in Square 1) are listed on Table 3.3 below 
Table 3.3: Observed data for GLM model and the potential outcome values for the sequences in Square 
1 
Time Period 1 Time Period 2 Time Period 3 
Sequences GLM POT. OUT GLM POT. OUT GLM POT. OUT 
TTC 11iy  ( )1i iX t+  21iy  ( )2i iX t+  31iy  ( )3i iY + τ  
TCT 12iy  ( )1i iX t+  22iy  ( )2i iY + τ  32iy  ( )3i iX t+  
CTT 13iy  ( )1i iY + τ  23iy  ( )2i iX t+  33iy  ( )3i iX t+  
 
Using the model (1.17) we have that, 
Sequence TTC: 
( ) ( )11 1 1 111 1i ii iy = µ + η + pi + θ + ηθ + ε  
( ) ( )21 2 1 211 1i ii iy = µ + η + pi + θ + ηθ + ε  
( ) ( )31 3 2 311 2i ii iy = µ + η + pi + θ + ηθ + ε  
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Sequence TCT: 
( ) ( )12 1 1 122 1i ii iy = µ + η + pi + θ + ηθ + ε  
( ) ( )22 2 2 222 2i ii iy = µ + η + pi + θ + ηθ + ε  
( ) ( )32 3 1 322 1i ii iy = µ + η + pi + θ + ηθ + ε  
Sequence CTT: 
( ) ( )13 1 2 133 2i ii iy = µ + η + pi + θ + ηθ + ε  
( ) ( )23 2 1 233 1i ii iy = µ + η + pi + θ + ηθ + ε  
( ) ( )33 3 1 333 1i ii iy = µ + η + pi + θ + ηθ + ε  
 
Proposition 3.7 
Given the model (1.17) and the potential outcomes observed data, the difference between 
the least square mean of the treatment effects is an unbiased estimate of the mean of the observed 
treatment effect (hence, an unbiased estimate of the true mean treatment effect). Let 
1 2 3,   and n n n  be the number of subjects in sequences TTC , TCT  and CTT  respectively. We 
assume 1 2 3n n n n= = = . Define 1ˆθ  and 2ˆθ  as 
( ) ( ) ( )31 211 21 12 32 23 33
1 1 1
1
1 2 3
1
ˆ
3 2 2 2
nn n
i i i i i i
i i i
y y y y y y
n n n
= = =
 
+ + + 
 θ = + +
 
  
∑ ∑ ∑
 (1.18) 
and  
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31 2
31 22 13
1 1 1
2
1 2 3
1
ˆ
3
nn n
i i i
i i i
y y y
n n n
= = =
 
 
 θ = + +
 
  
∑ ∑ ∑
 (1.19) 
 then, 
1 2
ˆ ˆ dθ − θ =  
where d  is the observed mean treatment effect from the potential outcome method.  
Proof: 
( ) ( ) ( )31 211 21 12 32 23 33
1 1 1
1
1 2 3
1
ˆ
3 2 2 2
nn n
i i i i i i
i i i
y y y y y y
n n n
= = =
 
+ + + 
 θ = + +
 
  
∑ ∑ ∑
 
( ) ( )( ) ( ) ( )( ) ( ) ( )( )31 21 2 1 3 2 3
1 1 1
1
1 2 3
1
ˆ
3 2 2 2
nn n
i i i i i i i i i i i i
i i i
X t X t X t X t X t X t
n n n
′ ′′= = =
 
+ + + + + + + + + 
 ⇒θ = + +
 
  
∑ ∑ ∑
 
( ) ( ) ( )31 22 1 1 3 2 3
1 1 1
1
1 2 3
2 2 2
1
ˆ
3 2 2 2
nn n
i i i i i i i i i
i i i
X t t X t t X t t
n n n
= = =
 
+ + + + + + 
 ⇒θ = + +
 
  
∑ ∑ ∑
.  
Similarly,  
( ) ( ) ( )31 23 2 1
1 1 1
2
1 2 3
1
ˆ
3
nn n
i i i i i i
i i i
Y Y Y
n n n
= = =
 
+ τ + τ + τ 
 θ = + +
 
  
∑ ∑ ∑
.  
Hence,  
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( ) ( ) ( )31 22 1 1 3 2 31 2 3 2 1
1 1 11 2 3
2 2 21 1 1 1
ˆ ˆ
3 2 2 2
nn n
i i i i i i i i i
i i i i i i
i i i
X t t X t t X t tY Y Y
n n n
= = =
 + + + + + +     θ −θ = − +τ + − +τ + − +τ      
      
∑ ∑ ∑  
( ) ( ) ( )31 22 1 1 3 2 31 2 3 2 1
1 1 11 2 3
1 1 1 1
ˆ ˆ
3 2 2 2
nn n
i i i i i i
i i i i i i i i i
i i i
t t t t t tX Y X Y X Y
n n n
= = =
 + + +     θ −θ = − + −τ + − + −τ + − + −τ      
      
∑ ∑ ∑  
Now, 1 2 3n n n n= = =  
( ) ( ) ( )2 1 1 3 2 31 2 3 3 2 2 1 1
1 1 1
1 1 1 1
ˆ ˆ
3 2 2 2
n n n
i i i i i i
i i i i i i i i i i i i
i i i
t t t t t tX Y X Y X Y
n n n
= = =
+ + +      θ −θ = − + −τ δ + − + −τ δ + − + −τ δ      
      
∑ ∑ ∑  
( ) 31 2
1 1 1
1
ˆ ˆ
2
n n
ij
i i ij ij
i i j
t
X Y
n
= = =
  
⇒θ −θ = − − +τ δ  
  
∑ ∑∑  .       
And from (1.3),  
1 2
1
1
ˆ ˆ
n
i
i
d d
n
=
θ −θ = =∑                                                                                                                           
 
Remark 3.5 
A similar correspondence between estimates of time effects in a repeated measure 
framework and the potential outcome framework was also noted and shown in a numerical 
illustration.  
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3.9.1: Illustrative Example 4: Comparing Potential Outcome with Repeated Measures   
Estimates  
We continue with Example 2 with application of the generalized mixed model (1.17) with 
repeated measures. We obtain 1 9.82mmHgd = , 2 9.87mmHgd = with standard errors of 
0.1722 and 0.2245 for the randomization in Squares 1 and 2 respectively. Furthermore, for the 
combined data, we have 12 9.88mmHgd = with a standard error of 0.1581. Thus, as stated in 
Proposition 3.7, the GLM estimates are equal to the potential outcomes estimates. That is, we 
may think of the PROC GLM or PROC MIXED outputs as estimates of the true population mean 
treatment effects. Furthermore, from the GLM output, the p-value is less than 0.0001, hence, 
there is evidence that X Yµ µ> .  
We also compared the estimates of the linear combination of the time effects parameters 
as explained in Corollary 3.5. Using the potential outcome method on subjects in the first and 
third sequences of Square 1, we have estimates: 1 2 2.127t t
Λ
− = − , 1 3 16.650t t
Λ
− =  and 
2 3 2 12 18.777t t t t
Λ Λ
− = + = . Similarly, for Square 2 we have estimates: 1 2 1.043
Λ
τ − τ = − , 
1 3 3.693
Λ
τ − τ =  and 2 3 4.737
Λ
τ − τ = .  
Using all the sequences in square 1, the estimates of the period contrasts produced by 
GLM are 1 2ˆ ˆ 2.124pi − pi = − , 1 3ˆ ˆ 16.654pi − pi =  and 2 3ˆ ˆ 18.779pi − pi =  with standard error 
0.2812 in all cases. For Square 2, SAS Proc GLM gives estimates: 1 2ˆ ˆ 0.932pi − pi = − , 
1 3ˆ ˆ 3.916pi − pi =  and 2 3ˆ ˆ 4.848pi − pi = , all, with standard error 0.23358.  
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In this chapter and chapter 2, we estimated the true individual treatment effect variability 
and the probability of negative effects for quantitative response variable using the method of 
potential outcomes. The analyses employed the two treatments, two periods and the two 
treatments, three periods randomizations. Furthermore, we compared the potential outcome 
estimates with the usual repeated measures estimates gotten using GLM. In the following 
chapter, we extend our analyses to qualitative response, precisely, the binary response variables. 
We limit the analyses to two treatments, two periods TC – CT and the TC – CT – TT – CC 
designs. For these designs, we will estimate the average treatment effect and the probability of 
negative effect – a component that implicitly reflects the individual treatment effect variability. 
Earlier, we saw that some work had been done these designs by Gadbury et al. (2004). However, 
their analyses assumed “exchangeability.” Initially, we relax the exchangeability assumption and 
later consider it. We show that, when the exchangeability assumption is factored into our 
analyses, the “without – exchangeability” analyses boils down to the analyses presented in the 
paper Gadbury et al. (2004).   
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CHAPTER 4 -  Analysis Using Binary Data 
4.0: Two Treatments, Two Periods with Binary Outcome  
In this chapter, we will base our analyses on two treatments, two periods with a binary 
response. The focus will be on the designs: TC – CT and TC – CT – TT – CC. The first part of 
the analyses will deal with the TC – CT crossover design for which we will estimate the true 
average treatment effect and construct bounds for an inestimable “probability of negative effect.” 
The second part involves the design, TC – CT – TT – CC. That is, some subjects will stay on the 
same treatment over the two periods. Observed responses from these subjects will enable us to 
construct tighter bounds for the probability of a negative effect. The expression of “probability of 
negative effect” carries a connotation of an “unexplained individual treatment variation” 
(Gadbury et al, 2004). An example will be used for illustrations. 
 
4.1:  A Two Treatment Design with Binary Response: One Time Point 
Let X and Y represent the response to treatments T and C  respectively. We let “1” 
denote “success” and “0” denote “failure.”  In addition, let ( ),X Y  be a set of bivariate discrete 
potential outcomes from an infinite population of outcomes. The joint discrete probability 
distribution of ( ),X Y , ( ),  P X x Y y= = , is given as on Table 4.1 below (Gadbury et al., 
2004). 
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Table 4.1: Joint Probability distribution of ( ),x y  
( ),x y
 
( )0,0  ( )0,1  ( )1,0  ( )1,1  Total 
( ),P X x Y y= =  1ω  2ω  3ω  4ω  
4
1
1i
i=
ω =∑  
 
where ( ),x y  are the observed outcomes of ( ),X Y  and ( ), iP X x Y y= = = ω , ( )1,2,3,4i = , 
is the true probability of ( ),x y  for an individual at a specific time. Since only one of either X or 
Y is measured at a specific time (the fundamental problem of causal inference), [ ]0,1iω ∈  
cannot be directly estimated for 1,2,3,4i =  separately. 
As before, define D X Y= −  as the true treatment (causal) effect. That is, D  expresses 
the actual effect of T relative to C  and note that D is not observable. Let ( )P D  denote the 
probability of D . Note that ( )P D  is a discrete probability distribution. Possible values of D  
and the associated probabilities are listed in Table 4.2 and 4.3 below  
Table 4.2: Possible values of D  
( ),x y
 
( )0,0
 
( )0,1
 
( )1,0
 
( )1,1
 
D X Y= −  0  1−  1  0  
 
For example, 1D = −  means treatment T leads to an unfavorable effect(failure) relative to 
treatment C  at a particular time.  
Table 4.3: Probability of observing D   
D
 
1−  0  1  
( )P D
 
2ω  1 4ω + ω  3ω  
 
 
 
  
 63 
Remark 4.1.1 
Let ( )1p E X=  and ( )2p E Y=  be the mean of the marginal distributions of X  and Y , 
and note that these are estimable. Then from Table 4.3, ( )1 3 41p P X= = = ω + ω  and 
( )2 2 41p E Y= = = ω + ω . Denote the true average individual treatment effect of T relative to 
C  as ( )E D .  Then, 
( ) 3 2 1 2E D p p= ω − ω = − . 
Note that ( )E D  represents the true mean treatment effect of T relative to C  at a particular 
time.  
For example, ( ) 0.6E D =  could mean several things 
1). 3 20.60  0andω = ω = : That is, 60% of the patients will succeed on T  but fail on C and the 
remaining 40% will either succeed on both T and C or fail on both T and C . 
2). 3 20.65  0.05andω = ω = : That is, 65% of the patients will succeed on T and fail on C , 5%  
will succeed on C  and fail on T and 30% will either succeed on both T and C or fail on both 
T and .C  
3). 3 20.80  0.20andω = ω = : 80% of the patients will succeed on T  and fail on C , 20%  will 
succeed on C  and fail on
 
T  and 0% will either succeed on both T and C or fail on both T and 
.C  
So, if the average treatment effect probability equals 0.60 does not immediately imply C  
is completely ineffective as (1) may suggest. Notice that (3) indicates 20% responded well on C  
and fail on T .  
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Remark 4.1.2 
The variance of the true individual treatment effect is given as 
( ) ( ) ( )
( )
( ) ( )
22
2
2 3 3 2
2 2 3 3 2 3
           
           1 1 2
Var D E D E D= −
= ω + ω − ω − ω
= ω − ω + ω − ω + ω ω
 
( )Var D  cannot be estimated because D  cannot be observed. In this chapter, less focus will be 
placed on ( )Var D  although we will establish bounds for it. Furthermore, we move the analysis 
of ( )Var D  to the appendix section of this dissertation. Instead, we will focus on estimating the 
probability of negative individual treatment effect, ( )0P D <  – a component that results from 
the variability of the individual effect – and the average individual treatment effect of T relative 
to C . In addition, the variance of a discrete distribution, usually, is a function of the mean. 
These make ( )Var D  difficult to interpret.  
In the next section, we present the two treatments, two periods TC – CT crossover design 
for binary outcomes.  Results will be outlined with and without the assumptions of 
“exchangeability.”  
 
4.2: Two Treatments Two Periods: Potential Outcomes and True Probabilities  
The prior section established the potential outcomes framework for a particular time 
point. This section considers two time points periods, so potential outcome variables are in four 
dimensions with ( )1 1,X Y  for time point Period 1 and ( )2 2,X Y  for time point Period 2. Thus, 
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there is a true individual treatment effects for both periods, given by 1 1 1D X Y= −  and 
2 2 2D X Y= − . It will be assumed that the bivariate marginal distribution for each time period 
will be given as in Table 4.4. However, in the 4 – dimensional joint distribution, exchangeability 
of bivariate outcomes may not hold due to time effects. Initially, it is assumed that 
exchangeability does not hold. As stated above, suppose there are two treatments T and C  with 
binary response, Table 4.4 below shows a constructed distribution of all possible potential 
outcomes for a population. 
Table 4.4: Potential outcomes framework and probabilities of two treatments, two periods crossover 
design 
 Period 2  
For an 
Individual ( ) ( )
 
2 2, 0,0
T C
x y =  ( ) ( ) 2 2, 0,1
T C
x y =  ( ) ( ) 2 2, 1,0
T C
x y =  ( ) ( ) 2 2, 1,1
T C
x y =  
Marginal 
Total 
  
( ) ( )                    1 1, 0,0
T C
x y =  11β  12β  13β  14β  1ω  
Per.1 ( ) ( )
  
1 1, 0,1
T C
x y =  21β  22β  23β  24β  2ω  
( ) ( ) 1 1, 1,0
T C
x y =  31β  32β  33β  34β  3ω  
( ) ( ) 1 1, 1,1
T C
x y =  41β  42β  4 3β  44β  4ω  
 
Marginal 
Total 1ω  2ω  3ω  4ω  1ω =∑  
 
From Table 4.4, we note that marginal distributions are assumed equal. That is,  
( ) ( )1 1 2 2, ,i i i i iP X x Y y P X x Y y= = = ω = = =  for 1,2,3,4i = . Furthermore,  
( ) ( ) ( ) ( )1 1 2 2, , , , ,ij i i j jP X Y x y X Y x y β = = =   for , 1,2,3,4i j =  is the true joint probability 
of ( )1 1,X Y  outcomes in Period 1 and ( )2 2,X Y  outcomes in Period 2 ( as on Table 4.4). Note 
here that, “ i ” goes with the row outcomes in Period 1 while “ j ” is associated with the columns 
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outcomes in Period 2. So, ijβ  is the actual probability of the thi  outcome in Period 1 and the thj  
outcome in Period 2, as given on Table 4.4.  In addition, [ ]0,1ijβ ∈  is inestimable for 
, 1,2,3,4i j = , since we cannot observed both ( )1 1,X Y  and ( )2 2,X Y , simultaneously. For 
example ( ) ( ) ( ) ( )11 1 1 2 2, 0,0 , , 0,0P X Y X Yβ = = =    is the true probability that both treatments 
are ineffective in periods 1 and 2 and ( ) ( ) ( ) ( )23 1 1 2 2, 0,1 , , 1,0P X Y X Yβ = = =    is the true 
probability of succeeding on C and failing on T  in Period 1 and succeeding on T  and on failing 
C  in Period 2. These probabilities cannot be estimated. 
 
Remark 4.2.1 
Additional remarks about Table 4.4: 
1). The true probability of potential outcomes at one period, conditioned on the outcomes at 
another period are the same, regardless of which period is conditioned, as long as the outcomes 
are the same at each period. That is,  
( ) ( ) ( ) ( ) ( ) ( ) ( ) ( )2 2 1 1 1 1 2 2, , , , , , , ,iii i i i i i i i
i
P X Y x y X Y x y P X Y x y X Y x yβ= = = = = =      ω , 
for 1,2,3,4i = .  
2). Exchangeability occurs when 
( ) ( ) ( ) ( ) ( ) ( ) ( ) ( )1 1 2 2 2 2 1 1, , , , , , , , , ,ij i i j j i i j j jiP X Y x y X Y x y P X Y x y X Y x y   β = = = = = = = β   
 
 We will reserve the detailed look at the notion of exchangeability for the later part of the 
dissertation. However, it is worthwhile noting that, for , 1,2,3,4i j = : 
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( ) ( ) ( ) ( ) ( ) ( ) ( ) ( )2 2 1 1 1 1 2 2, , , , , , , ,j j i i i i j jP X Y x y X Y x y P X Y x y X Y x y   = = ≠ = =    , 
unless i j= . 
This difference in probabilities suggests a possible time period effect or a dependency of 
outcomes in one period on outcomes in the other. Notice that with the assumption of 
exchangeability, the conditional probability effect is same regardless of the time period the 
treatment is administered.  
 
Marginal Probability 
The distribution of Table 4.4 has been constructed such that, even in the absence of 
exchangeability, the row and column probabilities for an individual in a given period sum to iω  
as presented on the Table 4.4. That is, 
4 4
1 1
ij i ij
j i= =
β = ω = β∑ ∑  and 
4
1
1i
i=
ω =∑ . 
 
Remark 4.2.2 
Having defined the distribution on Table 4.4, in the following sections, we use this 
distribution to study our observed data from the TC – CT (Section 4.3) and the TC – CT – TT – 
CC (Section 4.6) designs. We will express the probabilities of observing a particular outcome as 
a function of the actual probabilities on Table 4.4. Estimates of these estimable probabilities of 
observing an outcome will be found. In the first part of the analyses, we assume exchangeability 
condition does not hold (Section 4.5, 4.7). Later, we assume that it does hold and show that the 
analyses become that presented in Gadbury et al. (2004). 
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4.3:  Potential Outcomes and Probabilities of Observed Outcomes for the TC 
– CT Design  
Consider the two treatments, two periods crossover design.  The observed data will be of 
the form 
           
          1         2
  
1
    
2
Period
T C
Sequence
C T
 
The following schematic diagram illustrates the possible observed outcomes under the TC – CT 
design: 
                                   Sequence                  Period 1             Period 2 
                                       T C                      1 1X =                 2 1Y =    
                                                                   1 0X =                2 0Y =  
 
                                       C T                       1 1Y =                2 1X =  
                                                                    1 0Y =               2 0X =         
       
The options below illustrate the possible probabilities ( ) 1,2,...,4; 1,2ki i kφ = =  for the thi  
observed outcome in the thk  sequence expressed in terms of the true probability values ijβ  on 
Table 4.4. Hereafter, we will label these probabilities of observed data, “Estimable 
Probabilities.” 
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 TC – Sequence (1):  
1.) 
Estimable Probability Potential Outcomes  
 Period 1 Period 2  
( )11 1 20 ,  0P X Yφ = = =  ( )1 1 10 ,  X Y y= =  ( )2 2 2 ,  0X x Y= =  Probability 
 0             0 0           0 11β  
 0             0 1           0 13β  
 0             1 0           0 21β  
 0             1 1            0 23β  
Thus, ( )11 00 1 2 11 13 21 230 ,  0TC P P X Yφ = = = = = β + β + β + β  
2.) 
Estimable Probability Potential Outcomes  
 Period 1 Period 2  
( )12 1 20 ,  1P X Yφ = = =  ( )1 1 10 ,  X Y y= =  ( )2 2 2 ,  1X x Y= =  Probability 
 0             0 0           1 12β  
 0             0 1           1 14β  
 0             1 0           1 22β  
 0             1 1            1 24β  
( )12 01 1 2 12 14 22 240 ,  1TC P P X Yφ = = = = = β + β + β + β  
3.) 
Estimable Probability Potential Outcomes  
 Period 1 Period 2  
( )13 1 21 ,  0P X Yφ = = =  ( )1 1 11 ,  X Y y= =  ( )2 2 2 ,  0X x Y= =  Probability 
 1             0 0           0 31β  
 1             0 1           0 33β  
 1             1 0           0 41β  
 1             1 1            0 43β  
( )13 10 1 2 31 33 41 431 ,  0TC P P X Yφ β β β β= = = = = + + +  
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4.)  
Estimable Probability Potential Outcomes  
 Period 1 Period 2  
( )14 1 21 ,  1P X Yφ = = =  ( )1 1 11 ,  X Y y= =  ( )2 2 2 ,  1X x Y= =  Probability 
 1             0 0           1 32β  
 1             0 1           1 34β  
 1             1 0           1 42β  
 1             1 1            1 44β  
( )14 11 1 2 32 34 42 441 ,  1TC P P X Yφ = = = = = β + β + β + β  
Similarly, for sequence CT, 
CT  – Sequence (2):  
5.) 
Estimable Probability Potential Outcomes  
 Period 1 Period 2  
( )21 2 10 ,  0P X Yφ = = =  ( )1 1 1 ,  0X x Y= =  ( )2 2 20 ,  X Y y= =  Probability 
 0             0 0           0 11β  
 0             0 0           1 12β  
 1             0 0           0 31β  
 1             0 0            1 32β  
( )21 00 2 1 11 12 31 320 ,  0CT P P X Yφ = = = = = β + β + β + β  
6.) 
Estimable Probability Potential Outcomes  
 Period 1 Period 2  
( )22 2 1 X 0 ,  1P Yφ = = =  ( )1 1 1 ,  1X x Y= =  ( )2 2 20 ,  X Y y= =  Probability 
 0             1 0           0 21β  
 0             1 0           1 22β  
 1             1 0           0 41β  
 1             1 0            1 42β  
( )22 10 2 1 21 22 41 42X 0 ,  1CT P P Yφ = = = = = β + β + β + β  
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7.) 
Estimable Probability Potential Outcomes  
 Period 1 Period 2  
( )23 2 1X 1 ,  0P Yφ = = =  ( )1 1 1 ,  0X x Y= =  ( )2 2 21 ,  X Y y= =  Probability 
 0             0 1           0 13β  
 0             0 1           1 14β  
 1             0 1           0 33β  
 1             0 1            1 34β  
( )23 01 2 1 13 14 33 34X 1 ,  0CT P P Yφ = = = = = β + β + β + β  
8.) 
Estimable Probability Potential Outcomes  
 Period 1 Period 2  
( )24 2 1X 1 ,  1P Yφ = = =  ( )1 1 1 ,  1X x Y= =  ( )2 2 21 ,  X Y y= =  Probability 
 0             1 1           0 23β  
 0             1 1           1 24β  
 1             1 1           0 43β  
 1             1 1            1 44β  
( )24 11 2 1 23 24 43 44X 1 ,  1CT P P Yφ = = = = = β + β + β + β  
In summary, the estimable probabilities of the four possible observed outcomes from each 
sequence are 
Sequence (1) TC: 
                            ( )11 00 1 2 11 13 21 230 ,  0TC P P X Yφ = = = = = β + β + β + β               (1.20)    
                                  ( )12 01 1 2 12 14 22 240 ,  1TC P P X Yφ = = = = = β + β + β + β           (1.21) 
                                  ( )13 10 1 2 31 33 41 431 ,  0TC P P X Yφ = = = = = β + β + β + β               (1.22)                             
                             ( )14 11 1 2 32 34 42 441 ,  1TC P P X Yφ = = = = = β + β + β + β                (1.23) 
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Sequence (2) CT: 
                           ( )21 00 2 1 11 12 31 320 ,  0CT P P X Yφ = = = = = β + β + β + β               (1.24)   
                           ( )22 10 2 1 21 22 41 42X 0 ,  1CT P P Yφ = = = = = β + β + β + β                (1.25) 
                                ( )23 01 2 1 13 14 33 34X 1 ,  0CT P P Yφ = = = = = β + β + β + β                (1.26)           
                           ( )24 11 2 1 23 24 43 44X 1 ,  1CT P P Yφ = = = = = β + β + β + β                 (1.27) 
 
Remark 4.3.1 
1.) We note that, 
4
1
1ki
i=
φ =∑  for 1,2k = , [ ]0,1kiφ ∈  since 
4 4 4 4
1 1 1 1
1ki ij i
i i j i= = = =
φ = β = ω =∑ ∑∑ ∑ .  
2.) If arbitrary labeling of the time periods was possible, then, ij jiβ = β  for i j≠  and 
, 1,2,3,4i j = . This would imply exchangeability holds and thus, we can equate probabilities 
from the two sequences. For example, consider the outcome ( )1 21 ,  0X Y= =  in (1.22) above 
and ( )2 1X 1 ,  0Y= =  in (1.26), if exchangeability was possible then 13 31β = β , 34 43β = β  and 
hence, 13 10 01 23TC CTP Pφ = = = φ . This would suggest no sequence effect for the subjects with 
this outcome. But the reverse is not sufficiently true. That is, if 10 01TC CTP P=  does not directly 
imply exchangeability. That is,  
 ( ) ( ) ( )13 31 34 43 13 10 01 23 and TC CTP P⇒β = β β = β φ = = = φ⇐  
This relationship is true for all other combinations of probabilities involving the two sequences. 
The proof will be outlined later. 
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4.3.1: Analysis of the Estimable Probabilities, kiφ , of the Observed Outcomes 
Here is a more detailed look at the probabilities, ( ) 1,2,...,4; 1,2ki i kφ = = , for the thi  
observed outcome in the thk  sequence expressed in terms of the true or actual probability values 
ijβ  on Table 4.4. The probabilities are given in equations (1.20) through (1.27) above. Below, 
kiφ are expressed in terms of the marginal probabilities, iω  and the actual joint probabilities ijβ , 
for 1,2,...,4;  1,2 and 1,2i j k= = = . Inferences will then be drawn from the established 
relationships after some algebraic manipulations. For example, 
( ) ( )
11 11 13 21 23
1 21 12 23 14
1 1
    
    
φ = β + β + β + β
= ω + β − β + β − β
= ω − ∆
               
from the fact that ( ) ( )1 11 12 13 14 11 13 1 12 14ω = β + β + β + β ⇒ β + β = ω − β + β . Note that 
( ) ( )1 12 21 14 23∆ = β − β + β − β . This derivation involving 1ω  was established using the Period 1 
marginal. We can easily extend it to 2 3 4,   and ω ω ω . Due to the assumption of equality in 
marginals, similar equations, for the two sequences TC and CT, can be found using Period 2 
marginals (that is, column totals in Table 4.4). This is addressed in the following two columns: 
Using time Period 1 marginals in sequence TC      Using time Period 2 marginals in sequence TC 
11 1 1φ = ω − ∆                                         (1.28)        11 1 3φ = ω − ∆                                            (1.29) 
12 2 1φ = ω + ∆                                        (1.30)        12 2 4φ = ω + ∆                                           (1.31) 
13 3 2φ = ω + ∆                                        (1.32)        13 3 3φ = ω + ∆                                           (1.33) 
14 4 2φ = ω − ∆                                        (1.34)        14 4 4φ = ω − ∆                                          (1.35) 
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Using time Period 1 marginals in sequence CT      Using time Period 2 marginals in sequence CT 
21 1 5φ = ω − ∆                                          (1.36)        21 1 7φ = ω − ∆                                          (1.37) 
22 2 6= + ∆φ ω                                          (1.38)        22 2 7φ = ω + ∆                                         (1.39) 
23 3 5φ = ω + ∆                                          (1.40)        23 3 8φ = ω + ∆                                         (1.41) 
24 4 6φ = ω − ∆                                          (1.42)        24 4 8φ = ω − ∆                                         (1.43) 
where, 
( ) ( )1 12 21 14 23∆ = β − β + β − β , ( ) ( )2 43 34 41 32∆ = β − β + β − β , ( ) ( )3 31 13 41 23∆ = β − β + β − β , 
( ) ( )4 24 42 14 32∆ = β − β + β − β , ( ) ( )5 13 31 14 32∆ = β − β + β − β , ( ) ( )6 42 24 41 23∆ = β − β + β − β ,  
( ) ( )7 21 12 41 32∆ = β − β + β − β , ( ) ( )8 34 43 14 23∆ = β − β + β − β . 
 
Remark 4.3.1.1 
From Equations (1.28) through (1.35), there are some noticeable equalities between the 
equations to be considered. For instance, Equations (1.28) and (1.29) imply 1 3 0∆ − ∆ = . 
Similarly, we note that, 1 4 0∆ − ∆ = , 2 3 0∆ − ∆ =  and 2 4 0∆ − ∆ = . For example,  
( ) ( ) ( ) ( )1 3 12 21 14 23 31 13 41 23 1 11 1 11 0∆ − ∆ = β − β + β − β − β − β + β − β = ω − β − ω − β = . 
Furthermore, it can also be showed that, ( ) ( )1 4 2 22 2 22 0∆ − ∆ = ω − β − ω − β = , 
( ) ( )2 3 3 33 3 33 0∆ − ∆ = ω − β − ω − β =  and ( ) ( )2 4 4 44 4 44 0∆ − ∆ = ω − β − ω − β = . Hence, we 
note that, 1 2 3 4 TC∆ = ∆ = ∆ = ∆ = ∆  and, 5 6 7 8 CT∆ = ∆ = ∆ = ∆ = ∆ . Thus, as anticipated, any 
one of the two time period 1 and 2 marginals provides sufficient information about the actual or 
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true probability, iω , from the probabilities of observed outcomes, kiφ . Thus, (1.28) through 
(1.43) simplify to (1.48) through (1.51) given below.   
For sequence TC: 
11 1 TCφ = ω − ∆                                                 (1.44) 
12 2 TCφ = ω + ∆                                                (1.45) 
13 3 TCφ = ω + ∆                                                (1.46) 
14 4 TCφ = ω − ∆                                                (1.47) 
For sequence CT: 
21 1 CTφ = ω − ∆                                                (1.48) 
22 2 CTφ = ω + ∆                                                (1.49) 
23 3 CTφ = ω + ∆                                                (1.50) 
24 4 CTφ = ω − ∆                                               (1.51) 
From various combinations of (1.44) to (1.47) the TC∆  cancels out and we have, for 
sequence TC: 11 12 1 2φ + φ = ω + ω , 11 13 1 3φ + φ = ω + ω , 14 12 4 2φ + φ = ω + ω , 
13 14 3 4φ + φ = ω + ω  and for sequence CT: 21 22 1 2φ + φ = ω + ω , 21 23 1 3φ + φ = ω + ω , 
24 22 4 2φ + φ = ω + ω , 24 23 4 3φ + φ = ω + ω . Thus, linear combinations of iω  are estimable, 
although, separately iω  cannot be estimated even after applying the TC – CT randomization. 
This point is further reinforced by an attempt to calculate iω  using the matrix manipulations 
below.  Thus,  
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11 12 11 121 1
11 13 11 132 2
12 14 12 143 3
13 14 13 144 4
1 1 0 0
1 0 1 0
0 1 0 1
0 0 1 1
TCA
φ + φ φ + φω ω       
        φ + φ φ + φω ω        = ⇒ =
        φ + φ φ + φω ω
        φ + φ φ + φω ω        
 
where  
1 1 0 0
1 0 1 0
0 1 0 1
0 0 1 1
TC CTA A
 
 
 = =
 
 
 
. We note that the matrix TCA  (and hence, CTA ) is not a full-rank 
matrix since the sum 2nd and 3rd columns minus the first equals the 4th column. In addition, the 
Eigen values of TCA  (and hence, CTA ) are 2.000, 1.414, 0.000 and -1.414. Hence, no unique 
solution for iω  exist. In the next section, we derived estimates for the probabilities in Equations 
(1.44) to (1.51). 
 
4.4: Estimations Using Data of Observed Counts from a TC – CT Crossover 
Design 
In a typical TC – CT crossover design, the various possible observed outcomes and 
counts in Period 1 and 2 can be classified into ( ) ( ) ( ) ( )0,0 ,  0,1 ,  1,0 ,  1,1 , where ( ),a b  
indicates response “ a ”  in Period 1 and “ b ”  in  Period 2. In addition, for sequence TC , 
( ) ( )1 2, ,a b x y= . That is, a  represents response to T  in Period 1 and b  denotes response to C  
in Period 2. Meanwhile for sequence CT , ( ) ( )1 2, ,a b y x= . Thus, a  symbolizes response to C  
in Period 1 and b  signifies response to T  in Period 2. 
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 Let 1n •  and 2n •  denote the number of subjects assigned to sequence TC  and CT  
respectively. Also, let 11n , 12n , 13n , 14n , 21n , 22n , 23n , 24n  denote the number of subjects with 
response such that the first subscript correspond to the sequence and the second subscript 
enumerate the four outcomes. For example, 22n  denotes the number of subject that succeeded on 
treatment C in time Period 1 and failed on treatment T in time Period 2, meanwhile, 23n  denotes 
the number of subject that succeeded on treatment T in time Period 2 and failed on treatment C 
in time Period 1.  These counts are illustrated on Table 4.5 below.   
Table 4.5: Standard table of observed counts of responses to treatments in each period in a 2  
treatments, 2 periods crossover design with focus on sequence 
Sequence ( )0 ,  0  ( )0 ,  1  ( )1 ,  0  ( )1 ,  1  Marginal Total 
( )1 TC  11n  12n  13n  14n  1n •  
( )2 CT  21n  23n  22n  24n  2n •  
 
Notice the interchange between 22n  and 23n . Here, 22n  is the number of 
( )1 2,y x outcomes where ( )1 21, 0y x= =  and 23n  is the number of ( )1 2,y x outcomes with 
( )1,0 . This interchange was made to match the arrangement of outcomes ( )0,0 , ( )0,1 , ( )1,0  
and ( )1,1 . 
 
Remark 4.4.0 
Note that 
4
1i
ki kn n
=
•
=∑  for 1,2,3,4;  1,2i k= = .  Similarly, 
2 4
1 1k i
kin n
= =
=∑∑ , where n  
denoted the total sample size in both sequences. We note that period effect favors one treatment 
over the other when 12 13n n+  is substantially different from 22 23n n+  (Jones and Kenward, 
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1989, p. 93).  Inferentially, period effect, in favor of one treatment, is present when 12 13φ + φ  
differs substantially differs from 22 23φ + φ . We have that, 
( ) ( )
( ) ( )
12 13 1 2 1 2
12 14 22 24 31 33 41 43
0 ,  1 1 ,  0
            
P X Y P X Yφ + φ = = = + = =
= β + β + β + β + β + β + β + β  
( ) ( )
( ) ( )
22 23 2 1 2 1
21 41 22 42 13 33 14 34
0 ,  1 1 ,  0
            
P X Y P X Yφ + φ = = = + = =
= β + β + β + β + β + β + β + β  
In the presence of exchangeability, 12 13 22 23φ + φ = φ + φ  and there is no sequence or 
period effect. That is, time periods are randomly labeled. In the coming section, we explore 
methods of estimating the probabilities of the observed outcomes kiφ  for 1,2,3,4; 1,2i k= = .   
 
4.4.1: Maximum Likelihood Estimation of Probabilities Using Observed 
Count Data 
In the previous analysis involving the TC – CT crossover design, we got the estimable 
probabilities , kiφ , for 1,2,3,4; 1,2i k= = .  
We assume ( ) ( )1 2 3 4 1 2 3 4, , , , , ,k k k k k k k kn n n n multinomial φ φ φ φ∼ . The likelihood function of the 
observed data is given as 
( ) 2 41 2 3 4 1 2 3 4
1 1
, , , | , , , kink k k k k k k k ki
k i
L n n n n
= =
φ φ φ φ ∝ φ∏∏     ………………………. ( )∗  
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where  
4
1i
ki kn n
=
•
=∑ , for 1,2,3,4;  1,2i k= =  and subject to the constraints: 
4
1
1
1i
i=
φ =∑  
4
2
1
1i
i=
φ =∑ , 
and 12 21 22 11φ = φ + φ − φ , 23 11 13 21φ = φ + φ − φ  - a set of constraints that result from the 
following combinations of probabilities, kiφ , in design TC – CT:  
11 12 21 22φ + φ = φ + φ , 13 14 23 24φ + φ = φ + φ , 11 13 21 23φ + φ = φ + φ  and 12 14 22 24φ + φ = φ + φ  
 The likelihood expression in ( )∗  contains 4 distinct parameters leading to 4 nonlinear 
equations. Solving these equations requires an iterative numerical method subject to 4 
constraints. These 4 nonlinear equations could still be reparameterized with no constraints (as 
will be done in an illustrative example), but then, we would still require an iterative method of 
solution.  Various iterative numerical procedures are available for use. Here, we will use the 
optim package in R for evaluation (www.r-project.org). 
Assume the maximum likelihood estimates of the probabilities kiφ  have been found and 
denote them, ˆ kiφ , where 1,2,3,4; 1,2i k= = .  We state the following proposition: 
 
 
Proposition 4.4.1 
The average individual effect of treatment T relative to treatmentC , ( )E D , is given as 
( ) ( ) ( )13 23 12 220.5E D = φ + φ − φ + φ    and is estimated by  
( ) ( ) ( )13 23 12 22ˆ ˆ ˆ ˆ0.5E DΛ  = φ + φ − φ + φ   
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Proof: 
Recall that ( ) 3 2E D = ω − ω .  From equations (1.45) and (1.46) in sequence TC: 
( )3 2 13 12ω − ω = φ − φ . From equations (1.49) and (1.50) in sequence CT: 
( )3 2 23 22ω − ω = φ − φ . Thus, combining the effect from the two sequences, we have that,       
( ) ( ) ( )3 2 13 12 23 220.5E D = ω − ω = φ − φ + φ − φ   .  
( ) ( ) ( )13 12 23 22ˆ ˆ ˆ ˆ0.5E DΛ  ⇒ = φ − φ + φ − φ                                                                                                     
 
Remark 4.4.1 
( )E DΛ  is an estimate of ( )E D - the actual average individual treatment effect of T versus C  - 
in a TC CT− crossover design. ( )E D  expresses the average difference in response for the 
( )1,0  and ( )0,1  outcomes at a particular time point. We now turn our focus to the “probability 
of negative effect.”  
 
4.4.2: Probability of a Negative Effect 
Consider the probability of fairing well on treatment C  relative to treatment T . In this 
case, 0D X Y= − < .  From Table 6, the probability of negative effect is given as 2ω . That is, 
( ) 21P D = − = ω .  From Table 4.4, we have that, ( ) 2 21 22 23 241P D = − = ω = β + β + β + β  
(using Period 1 probabilities) or ( ) 2 12 22 32 421P D = − = ω = β + β + β + β  (using Period 2 
probabilities), where, ( )2 0,  1P X Yω = = = . The expression of probability of negative effect 
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carries a connotation of an “unexplained individual treatment variation” (Gadbury et al, 2004, p. 
173).  Furthermore, it may also provide information on the “possible magnitude of a treatment by 
covariate interaction” (Gadbury et al, 2004, p. 173), and treatment by period interaction, thus 
shedding more light on the extent of the unexplained individual treatment effect variability. 
 
Proposition 4.4.2 
For the TC – CT crossover design, the combined probability of a negative effect, 
( )12 01 1 20 ,  1TC P P X Yφ = = = =  and ( )22 10 2 1X 0 ,  1CT P P Yφ = = = =  is not an unbiased 
estimate of the actual probability of negative effect given as ( )2 0, 1P X Yω = = = .  
Proof: 
From equations (1.45) and (1.50), we have that 
( )( )2 12 220.5 TC CTω = φ + φ − ∆ + ∆                                                                                     (1.52) 
Thus, the probability of observing ( )0,1  is not unbiased for the true probability of ( )0,1  denoted 
2ω .  
 
Remark 4.4.2 
As a consequence of the proposition 4.4.3, we will establish bounds, [ ]1 1,L U , for the true 
probability of negative effect, ( )2 0, 1P X Yω = = = , since it is impossible to estimate 
( )TC CT∆ + ∆  using the TC – CT design.  This statement holds even with the inclusion of 
exchangeability because, then, TC CT∆ = ∆  - as will be shown later - and ( )TC CT∆ + ∆  does not 
cancel out. The next proposition builds on this remark.  
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Proposition 4.4.3 
The bounds for 2ω  using the TC – CT crossover design are 1L  and 1U  such that  
1 2 1L U≤ ω ≤  
where ( ) ( ){ }1 12 22 13 23max 0,  0.5L = φ + φ − φ + φ    and 
( ) ( ) ( ) ( ){ }1 11 21 22 12 14 2412 22min 0.5 ,  0.5U = φ + φ + φ + φ φ + φ + φ + φ        
Proof: 
From Equations (1.44) of sequence TC and (1.48) of sequence CT, we have, 11 12 1 2φ + φ = ω + ω  
and  21 23 1 2φ + φ = ω + ω  respectively. This leads us to the equation, 
( )1 2 11 12 21 230.5ω + ω = φ + φ + φ + φ . Similarly, from Equation (1.46): 14 12 4 2φ + φ = ω + ω , and 
Equation (1.50): 24 23 4 2φ + φ = ω + ω , we have  ( )4 2 14 12 24 230.5ω + ω = φ + φ + φ + φ . 
Hence,  
( ) ( ) ( ) ( ){ }2 11 21 22 12 14 2412 22min 0.5 ,  0.5Uω ≤ = φ + φ + φ + φ φ + φ + φ + φ       . 
Furthermore, we had that  ( ) ( )3 2 13 23 12 220.5ω − ω = φ + φ − φ + φ   . This implies 
( ) ( )2 3 12 13 22 230.5ω = ω + φ − φ + φ − φ    and thus, 
( ) ( ){ }2 12 22 13 23max 0,  0.5Lω ≥ = φ + φ − φ + φ                                                                          
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Proposition 4.4.4 
1L  and 1U
 
are identifiable and have M.L.E.s  given as 1ˆL  and 1ˆU where 
( ) ( ){ }1 12 22 13 23ˆ ˆ ˆ ˆˆ max 0,  0.5L  = φ + φ − φ + φ  and 
( ) ( ) ( ) ( ){ }1 11 21 12 22 12 22 14 24ˆ ˆ ˆ ˆ ˆ ˆ ˆ ˆˆ min 0.5 ,  0.5U    = φ + φ + φ + φ φ + φ + φ + φ     
where ˆ kiφ , ( )1,2,3,4 and 1,2i k= =  are MLE estimates of the probabilities kiφ . Furthermore, 
there exists a distribution for which 1L  and 1U  are attained. 
Proof: 
There exists a unique M.L.E for each ˆ kiφ , 1,2,3,4;  1,2i k= = . Thus, identifiability follows.  
We also note that, 
( ) ( ) ( ) ( ){ }
( ) ( ) ( ) ( )
( ) ( ) ( ) ( )
1 11 21 22 12 14 24
11 21 22 11 21 14 24
14 24 12 11 21 14 24
12 22
12
22
min 0.5 ,  0.5
0.5     
     
0.5    
U
if
if
= φ + φ + φ + φ φ + φ + φ + φ      
 φ + φ + φ + φ φ + φ ≤ φ + φ   
=  φ + φ + φ + φ φ + φ ≥ φ + φ   
 
 
These bounds are attained when the distribution of Table 4.4 leads to probability of observed 
outcomes shown on the Tables 4.6 and 4.7 below. 
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      Table 4.6: A distribution of probabilities of observed 
        outcomes for which the upper bound is be attained 
 
 
 
 
 
 
 
or 
      Table 4.7: A distribution of probabilities of observed 
      outcomes for which the lower bound is be attained 
 
 
 
 
 
 
 
respectively, where ( )1 11 21θ = φ + φ , ( )2 12 22θ = φ + φ , ( )3 13 23θ = φ + φ , ( )4 14 24θ = φ + φ .  
Similarly,  
( ) ( ){ }
( ) ( )
( ) ( ) ( ) ( )
1 12 22 13 23
12 22 13 23
12 13 23 12 22 13 2322
max 0,  0.5
0                                               
   
0.5    
L
if
if
= φ + φ − φ + φ  
 φ + φ ≤ φ + φ
=  φ + φ − φ + φ φ + φ ≥ φ + φ   
 
and the bounds are attained with a distribution of the forms, 
For an 
Indiv. ( )
    
0,0
T C
 ( ) 0,1T C  ( ) 1,0T C  ( ) 1,1T C  
( )    0,0T C  0 0 0 0 
( ) 0,1T C  0 20.5θ  0 0 
( ) 1,0T C  0 0 30.5θ  0 
( ) 1,1T C  0 0 0 40.5θ  
For an 
Indiv. ( )
    
0,0
T C
 
( ) 0,1T C
 
( ) 1,0T C
 
( ) 1,1T C
 
( )    0,0T C
 
10.5θ  0  0 0 
( ) 0,1T C
 
0 20.5θ  0 0 
( ) 1,0T C
 
0 0 30.5θ  0 
( ) 1,1T C
 
0 0 0 0 
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      Table 4.8: A distribution of probabilities of observed outcomes  
      for which the lower bound is be attained. 
       
   
 
 
 
 
or  
 
      Table 4.9: A distribution of probabilities of observed outcomes 
      for which the lower bound is be attained 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
respectively.                                                                                                                                
 We continue the analyses with the examination of the concept of exchangeability. We 
define certain criteria which will be useful, subsequently. Later in the analyses, we impose the 
exchangeability assumption and investigate the impact on the conclusions already reached. 
 
 
For an 
Indiv. ( )
    
0,0
T C
 
( ) 0,1T C
 
( ) 1,0T C
 
( ) 1,1T C
 
( )    0,0T C
 
( )1 20.5 θ +θ  0 0 0 
( ) 0,1T C
 
0 20.5θ  0 0 
( ) 1,0T C
 
0 0 ( )3 20.5 θ − θ  0 
( ) 1,1T C
 
0 0 0 40.5θ  
For an 
Indiv. ( )
    
0,0
T C
 
( ) 0,1T C
 
( ) 1,0T C
 
( ) 1,1T C
 
( )    0,0T C
 
40.5θ  0
 
0 0 
( ) 0,1T C
 
0 30.5θ  0 0 
( ) 1,0T C
 
0 0 ( )2 30.5 θ − θ  0 
( ) 1,1T C
 
0 0 0 ( )1 30.5 θ +θ  
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4.5: Exchangeability 
The notion of exchangeability can be explained in terms of the true probabilities ijβ  and 
estimable probabilities, kiφ , from the observed data, where , 1,2,3,4;  1,2i j k= = .  
First, exchangeability occurs when ij jiβ = β . Until now, we have assumed that exchangeability 
does not hold, that is, ij jiβ ≠ β  for i j≠  and , 1,2,3,4i j =  in Table 4.4.  
As a consequence of ij jiβ = β ,  we have exchangeability in the observed outcomes. That 
is, ki k i′φ = φ  for 1,2,3,4i =  and ( ), 1,2k k k k′ ′= ≠ . That is, if ij jiβ = β , then 
11 21 12 22,  ,φ = φ φ = φ  13 23 14 24 and φ = φ φ = φ .  
 In general, exchangeability may not be reasonable in a two – time period design. This is 
especially true in the presence of carryover and/or correlation between the outcomes in the first 
and second periods for a given treatment. The absence of exchangeability emphasizes the 
presence of time period effect. However, Gadbury et al. (2004) showed that exchangeability is 
reasonable with matched pairs because it is reasonable to assume subjects 1 and 2 within a pair 
are randomly labeled.  But applying this assumption to a two treatment, two periods crossover 
design would suggest the periods are randomly labeled.  
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4.5.1: Definition of Some Criteria 
Define the following criteria: 
1). periods - TC - perfect match if ( )1 1,x y and ( )2 2,x y are such that 1 2x x=  and 1 2y y= . From 
Table 4.4, the various combinations of outcomes are: 
 ( ) ( ){ } ( ) ( ){ }1 1 2 2, , , 0,0 , 0,0x y x y = , ( ) ( ){ } ( ) ( ){ }1 1 2 2, , , 0,1 , 0,1x y x y = , 
( ) ( ){ } ( ) ( ){ }1 1 2 2, , , 1,0 , 1,0x y x y = and ( ) ( ){ } ( ) ( ){ }1 1 2 2, , , 1,1 , 1,1x y x y = . 
The actual probabilities associated with these combinations of outcomes are 11β , 22β , 33β , 44β , 
respectively. These are the diagonal probabilities in Table 4.4. 
2). periods - TC - perfect mismatch if ( )1 1,x y and ( )2 2,x y are such that 1 2x x≠  and 1 2y y≠ . 
Combinations of outcomes in this domain include: 
 ( ) ( ){ } ( ) ( ){ }1 1 2 2, , , 0,1 , 1,0x y x y = , ( ) ( ){ }1,0 , 0,1 , ( ) ( ){ }0,0 , 1,1 and ( ) ( ){ }1,1 , 0,0 . These 
constitute the outcomes with cross-diagonal ( )↗  probabilities in Table 4.4. 
3). periods - T - match if ( )1 1,x y and ( )2 2,x y are such that 1 2x x=  and 1 2y y≠ . The following 
combinations of outcomes under this definition include: 
( ) ( ){ } ( ) ( ){ }1 1 2 2, , , 0,1 , 0,0x y x y = , ( ) ( ){ } ( ) ( ){ }1 1 2 2, , , 0,0 , 0,1x y x y = , 
( ) ( ){ } ( ) ( ){ }1 1 2 2, , , 1,0 , 1,1x y x y =  and ( ) ( ){ } ( ) ( ){ }1 1 2 2, , , 1,1 , 1,0x y x y = . 
4). periods - C - match if ( )1 1,x y and ( )2 2,x y are such that 1 2x x≠  and 1 2y y= . The following 
combinations of outcomes fall under this category:  
( ) ( ){ } ( ) ( ){ }1 1 2 2, , , 0,0 , 1,0x y x y = , ( ) ( ){ } ( ) ( ){ }1 1 2 2, , , 1,0 , 0,0x y x y = ,    
( ) ( ){ } ( ) ( ){ }1 1 2 2, , , 0,1 , 1,1x y x y =  and ( ) ( ){ } ( ) ( ){ }1 1 2 2, , , 1,1 , 0,1x y x y = . 
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Proposition 4.5.1 
Consider the true probabilities given on Table 4.4.  
If exchangeability holds (i.e. ij jiβ = β ), then ki k i′φ = φ  for , 1,2,3,4i j =  and
 
( ), 1,2k k k k′ ′= ≠ . 
Assume that the “periods - TC - perfect match” and “periods - TC - perfect mismatch” 
probabilities are zero. If ki k i′φ = φ  then exchangeability holds and we obtain ij jiβ = β . 
Proof: 
We will show the proof for one probability expression, 13 23φ = φ . The others follow likewise.  
 If ij jiβ = β   (for i j≠  and , 1,2,3,4i j = ), then from Table 4.4 and equations (1.19) to (1.26),  
we will have, for the first case, 
 
( )
( )
( )
13 10 1 2
31 33 41 43
13 33 14 34
10
2 1
23
1 ,  0
                 
                   since 
                 
                 1 ,  0
                 
TC
ij ji
CT
P P X Y
P
P X Y
φ = = = =
= β + β + β + β
= β + β + β + β β = β
=
= = =
= φ
 
This is true for all other combinations of probabilities. Hence, 12 01 10 22TC CTP Pφ = = = φ , 
14 11 11 24TC CTP Pφ = = = φ  and 11 00 00 21TC CTP Pφ = = = φ . 
If we assume “periods - TC - perfect match” and “periods - TC - perfect mismatch” 
probabilities are zero, then the diagonal and cross-diagonal ( )↗  probabilities are zero. That is, 
11 0β = , 22 0β = , 33 0β = , 44 0β = , 14 0β = , 23 0β = , 32 0β = , 41 0β = . Thus, Table 4.4 
becomes Table 4.8 shown below.  
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   Table 4.10: Probabilities of potential Outcomes for two treatments, two periods crossover design     
showing zero values for periods - TC - perfect match and periods - TC - perfect mismatch  
 Period 2  
For an 
Individual ( )
    
0 ,  0
T C
 ( )    0 ,  1T C  ( )    1 ,  0T C  ( )    1 ,  1T C  Marginal Total 
 
( )    0 ,  0T C  0  12β  13β  0  1ω  
Period 
1 ( )
    
0 ,  1
T C
 21β  0  0  24β  2ω  
( )    1 ,  0T C  31β  0  0  34β  3ω  
( )    1 ,  1T C  0  42β  43β  0  4ω  
 
Marginal 
Total 1ω  2ω  3ω  4ω  
4
1
1i
i=
ω =∑  
 
Equating the marginals, iω , on Table 14, we have the following equations 
12 13 21 31β + β = β + β  (1.53) 
21 24 12 42β + β = β + β  (1.54) 
31 34 13 43β + β = β + β  (1.55) 
42 43 24 34β + β = β + β  (1.56) 
 
Now, from (1.19) and (1.25), we had that  
( )
( )
13 10 1 2 31 33 41 43
31 43 33 41
1 ,  0
                                                       since 0,  0
TC P P X Yφ = = = = = β + β + β + β
= β + β β = β =  
( )23 01 2 1 13 14 33 34
13 34
X 1 ,  0
                                                    
CT P P Yφ = = = = = β + β + β + β
= β + β  
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So, if we assume 13 10 10 23TC CTP Pφ = = = θ , then,  
                                                31 43 13 34β + β = β + β  (1.57) 
But from Equation (1.56), 34 13 43 31β = β + β − β . Substituting into (1.58) and simplifying gives  
                                                    31 13 13 312 2β = β ⇒ β = β  (1.58) 
We can repeat the process for other probability expressions and obtain 12 21β = β , 14 41β = β , 
24 42β = β  and 34 43β = β . Thus, ij jiβ = β  for , 1,2,3,4i j = .                                                         
 
From the above proposition, we note that, exchangeability in the observed probability is a 
necessary but not a sufficient condition for exchangeability in the true probability. That is, 
exchangeability in the observed outcome is necessary for the actual exchangeability. But by 
itself, observed exchangeability is not sufficient. In symbols, ( ) ( )ij ji ki k i′⇒β = β φ = φ⇐ . 
 
Remark 4.5.1 
So far, we have looked at analyses of the TC – CT crossover design. We were able to 
express the probabilities of the observed outcomes, kiφ , in terms of the true or actual 
probabilities. Furthermore, we estimated the probabilities, kiφ , using observed count data. In 
addition, we constructed bounds for the probability of negative effect, 2ω , denoted [ ]1 1,L U . We 
note that, using the equation ( )( )2 12 220.5 TC CTω = φ + φ − ∆ + ∆ , a new – and hopefully, tighter 
– bounds, [ ]2 2,L U , for 2ω  can be found by first constructing bounds for ( )TC CT∆ + ∆  using 
information gained from additional analyses of the TT – CC design. Such bounds for 
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( )TC CT∆ + ∆  will also be useful in the construction of bounds for the true variance of the 
individual treatment effect, ( )Var D (see Appendix 4). Hereafter, we proceed with the analysis of 
an additional design:  TC – CT – TT – CC. Notice this is just an extension of the TC – CT 
crossover. 
 
4.6:  Potential Outcomes and Probabilities of Observed Outcomes for the TC 
– CT – TT –  CC Design  
             Suppose some patients are allowed to stay on the same treatment over the two periods 
resulting in the TT – CC. The new TC – CT – TT – CC design is an extension of the TC – CT 
crossover design. The randomization is of the form 
           
          1         2
  
1
    
2
Period
T C
Sequence
C T
      
           
          1         2
  
1
    
2
Period
T T
Sequence
C C
 
Consider the following schematic diagram illustrates the observed possible outcomes under the 
TC – CT design: 
                                   Sequence                  Period 1             Period 2 
                                       T C (1)                 1 1X =                2 1Y =    
                                                                   1 0X =                2 0Y =  
 
                                       C T (2)                 1 1Y =                 2 1X =  
                                                                    1 0Y =                2 0X =               
 
                                       T T (3)                 1 1X =                2 1X =  
                                                                    1 0X =               2 0X =               
 
  
 92 
                                       C C (4)                  1 1Y =                2 1Y =  
                                                                     1 0Y =               2 0Y =             
 
Earlier, we analyzed the probabilities of observed outcomes obtained using the TC – CT design. 
Below, we present the possible options for these probabilities for the TT – CC design.  
TT  – Sequence (3): 
Estimable Probability Potential Outcomes  
 Period 1 Period 2  
( )31 1 20 ,  X 0P Xφ = = =  ( )1 1 10 ,  X Y y= =  ( )2 2 20,  X Y y= =  Probability 
 0             0 0           0 11β  
 0             0 0           1 12β  
 0             1 0           0 21β  
 0             1 0           1 22β  
That is, ( )31 01 1 2 11 12 21 220 ,  X 0TT P P Xφ = = = = = β + β + β + β  
Similar breakdown results in the following probabilities for the respective observed outcomes: 
Sequence (3) TT: 
                            ( )31 01 1 2 11 12 21 220 ,  X 0TT P P Xφ = = = = = β + β + β + β                 (1.59)              
                               ( )32 01 1 2 13 14 23 240 ,  X 1TT P P Xφ = = = = = β + β + β + β                    (1.60) 
                              ( )33 10 1 2 31 41 32 421 ,  X 0TT P P Xφ = = = = = β + β + β + β                     (1.61)                                               
                             ( )34 11 1 2 33 34 43 441 ,  X 1TT P P Xφ = = = = = β + β + β + β                      (1.62) 
Sequence (4) CC:            
 ( )41 00 1 2 11 13 31 330 ,  0CC P P Y Yφ = = = = = β + β + β + β  (1.63)                                     
 ( )42 01 1 2 12 32 14 340 ,  1CT P P Y Yφ = = = = = β + β + β + β  (1.64)             
 ( )43 10 1 2 21 23 41 431 ,  0CC P P Y Yφ = = = = = β + β + β + β  (1.65)       
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       ( )44 11 1 2 22 24 42 441 ,  1CC P P Y Yφ = = = = = β + β + β + β  (1.66) 
From Equation (1.59) through (1.66) we infer the certain combinations, we express the following 
combination of probabilities: 31 32 1 2φ + φ = ω + ω , 31 33 1 3φ + φ = ω + ω , 34 33 3 4φ + φ = ω + ω , 
34 32 2 4φ + φ = ω + ω , 41 42 1 2φ + φ = ω + ω , 41 43 1 3φ + φ = ω + ω , 44 43 3 4φ + φ = ω + ω , 
44 42 3 4φ + φ = ω + ω . The following proposition gives bounds for the TC CT∆ + ∆  involving 
estimable probabilities in the TC – CT – TT – CC design. 
 
Proposition 4.6.1 
Under the framework established above, ( ) ( ){ }31 34 41 44min 1 ,1TC CT∆ + ∆ ≤ − φ + φ − φ + φ , 
where 12φ , 22φ , 31φ , 34φ , 41φ  and 44φ  are as given above. 
Proof: 
Recall that ( )31 1 20 ,  X 0P Xφ = = = , ( )34 1 21 ,  X 1P Xφ = = = , ( )41 1 20 ,  0P Y Yφ = = =  
and ( )44 1 21 ,  1P Y Yφ = = = . In addition, we saw that,  
( ) ( )1 12 21 14 23∆ = β − β + β − β , ( ) ( )2 43 34 41 32∆ = β − β + β − β , ( ) ( )3 31 13 41 23∆ = β − β + β − β , 
( ) ( )4 24 42 14 32∆ = β − β + β − β , ( ) ( )5 13 31 14 32∆ = β − β + β − β , ( ) ( )6 42 24 41 23∆ = β − β + β − β ,  
( ) ( )7 21 12 41 32∆ = β − β + β − β , ( ) ( )8 34 43 14 23∆ = β − β + β − β . Furthermore, we showed that 
 1 2 3 4 TC∆ = ∆ = ∆ = ∆ = ∆  and 5 6 7 8 CT∆ = ∆ = ∆ = ∆ = ∆ .  
Consider the 1 7 and ∆ ∆ combination. 
  
( ) ( )
1 7
14 23 41 32
14 41 23 32
               
               
TC CT∆ + ∆ = ∆ + ∆
= β − β + β − β
= β + β − β + β
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Note that, the expression, ( ) ( )14 41 23 32β + β − β + β  involve perfect – TC – mismatch 
probabilities, 14β , 41β , 23β  and 32β  corresponding to ( ) ( ){ } ( ) ( ){ }1 1 2 2, , , 0,0 , 1,1x y x y = , 
( ) ( ){ } ( ) ( ){ }1 1 2 2, , , 1,1 , 0,0x y x y = , ( ) ( ){ } ( ) ( ){ }1 1 2 2, , , 0,1 , 1,0x y x y = , and 
( ) ( ){ } ( ) ( ){ }1 1 2 2, , , 1,0 , 0,1x y x y = , respectively. Furthermore, using the principle of triangle 
inequality, we have ( ) ( )14 41 23 32TC CT∆ + ∆ ≤ β + β + β + β . But,  
( ) ( ) ( ) ( ) ( )
( ) ( )
( )
14 41 23 32 1 2 3 4 11 12 13 21 22 24
31 33 34 42 43 44
11 12 21 22
                                                                      
                                   1
β + β + β + β = ω + ω + ω + ω − β + β + β − β + β + β
− β + β + β − β + β + β
≤ − β + β + β + β + β( )
( ) ( )
( )
33 34 43 44
1 2 1 2
31 34
                                   1 0 ,  X 0 1 ,  X 1
                                   1
P X P X
+ β + β + β  
= − = = + = =  
= − φ + φ
 
Thus, ( ) ( ) ( )14 41 23 32 31 341β + β + β + β ≤ − φ + φ .  Similarly,  
( ) ( ) ( ) ( )
( ) ( )
( )
14 41 23 32 11 13 31 33 22 24 42 44
1 2 1 2
41 44
1
                                   1 0 ,  Y 0 1 , 1
                                   1
P Y P Y Y
β + β + β + β ≤ − β + β + β + β + β + β + β + β  
= − = = + = =  
= − φ + φ
 
Hence, ( ) ( ) ( )14 41 23 32 41 441β + β + β + β ≤ − φ + φ . Combining gives 
 ( ) ( ){ }31 34 41 44min 1 ,1TC CT∆ + ∆ ≤ − φ + φ − φ + φ                                                         (1.67)     
 
Remark 4.6.1 
The proof above uses the 1 7 and TC CT∆ = ∆ ∆ = ∆  combination although 
1 2 3 4 TC∆ = ∆ = ∆ = ∆ = ∆  and that 5 6 7 8 CT∆ = ∆ = ∆ = ∆ = ∆ . Other possible combinations 
like 2 8 3 5 4 6 and ;  and ;  and ∆ ∆ ∆ ∆ ∆ ∆  will produce the same results with varied degree of 
  
 95 
analysis. Equation (1.67) gives bounds for TC CT∆ + ∆ . These bounds will now be used to 
construct, hopefully tighter, bounds for the probability of negative effect 2ω  and (in Appendix 
D) the true variance individual treatment effects, ( )Var D   
 
Proposition 4.6.2 
Given that  ( ) ( ){ }31 34 41 44min 1 ,1TC CT∆ + ∆ ≤ − φ + φ − φ + φ , a refined set of bounds for 2ω is 
2 2 2L U≤ ω ≤
 
where, ( ) ( ) ( ){ }{ }2 12 22 31 34 41 44max 0,0.5 min 1 ,1L  = φ + φ − − φ + φ − φ + φ   and 
 ( ) ( ) ( ){ }2 12 22 31 34 41 440.5 min 1 ,1U  = φ + φ + − φ + φ − φ + φ  . 
Proof: 
( ) ( ){ }31 34 41 44min 1 ,1TC CT∆ + ∆ ≤ − φ + φ − φ + φ
( ) ( ){ } ( ) ( ) ( ){ }31 34 41 44 31 34 41 44min 1 ,1 min 1 ,1TC CT⇒ − − φ + φ − φ + φ ≤ ∆ + ∆ ≤ − φ + φ − φ + φ
 
But we showed that ( )( )2 12 220.5 TC CTω = φ + φ − ∆ + ∆ . Thus,  
( ) ( ) ( ){ }
( )( )
( ) ( ) ( ){ }
12 22 31 34 41 44
12 22
12 22 31 34 41 44
0.5 min 1 ,1
                    0.5
0.5 min 1 ,1
TC CT
 φ + φ − − φ + φ − φ + φ 
≤ φ + φ − ∆ + ∆ ≤
 φ + φ + − φ + φ − φ + φ 
 
2 2 2L U⇒ ≤ ω ≤ , 
where, ( ) ( ) ( ){ }{ }2 12 22 31 34 41 44max 0,0.5 min 1 ,1L  = φ + φ − − φ + φ − φ + φ   and 
 ( ) ( ) ( ){ }2 12 22 31 34 41 440.5 min 1 ,1U  = φ + φ + − φ + φ − φ + φ                                                      
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Proposition 4.6.3 (See Appendix D) 
 
         Consider an extended data of observed counts on Table 4.11 shown below. 
Table 4.11: Standard table of observed counts of responses to treatments in each 
 period in a 2 treatments, 2 periods crossover design with focus on sequence 
Sequence ( )0 ,  0  ( )0 ,  1  ( )1 ,  0  ( )1 ,  1  Marginal Total 
( )1 TC  11n  12n  13n  14n  1n •  
( )2 CT  21n  23n  2 2n  24n  2n •  
( )3 TT  31n  32n  3 3n  34n  3n •  
( )4 CC  41n  42n  4 3n  44n  4n •  
 
Estimating kiφ for the TC – CT – TT – CC design follows the same pattern involving iterative 
numerical evaluations. Consider the likelihood function for the TC – CT – TT – CC as developed 
below. 
Assume ( ) ( )1 2 3 4 1 2 3 4, , , , , ,k k k k k k k kn n n n multinomial φ φ φ φ∼  for
 
, 1,2,3,4i k = . The likelihood 
function is  
( ) 4 41 2 3 4 1 2 3 4
1 1
, , , | , , , kink k k k k k k k ki
k i
L n n n n
= =
φ φ φ φ ∝ φ∏∏     ………………………. ( )∗∗  
where  
4
1i
ki kn n
=
•
=∑ , for 1,2,3,4;  1,2i k= =  and subject to the two constraints:  
4
1
1
1i
i=
φ =∑ , 
4
2
1
1i
i=
φ =∑ , 
4
3
1
1i
i=
φ =∑  and 
4
4
1
1i
i=
φ =∑ . Other constraints are 12 21 22 11φ = φ + φ − φ , 
23 11 13 21φ = φ + φ − φ , 32 11 12 31φ = φ + φ − φ  and 42 21 23 41φ = φ + φ − φ  - restrictions that result 
from the following combinations of probabilities in observed outcomes for design TC – CT – TT 
– CC.  
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Thus, the likelihood function ( )∗∗  contains 8 distinct parameters leading to solving a system of 
8 nonlinear equations with 8 constraints. Further we may reparameterize into a system of 8 
nonlinear equations without constraints. However, like before, their solutions would require an 
iterative numerical method. Assuming estimates of kiφ , denoted ˆ kiφ , can be found, we proceed 
with stating estimates for the bounds. An estimate of the bounds, [ ]2 2,L U , for 2ω  is given as 
2 2
ˆ ˆ
,L U   , where, ( ) ( ) ( ){ }( )2 12 22 31 34 41 44ˆ ˆ ˆ ˆ ˆ ˆˆ max 0,0.5 min 1 ,1L  = φ + φ − − φ + φ − φ + φ   
 and ( ) ( ) ( ){ }2 12 22 31 34 41 44ˆ ˆ ˆ ˆ ˆ ˆˆ 0.5 min 1 ,1U  = φ + φ + − φ + φ − φ + φ  .  
 
4.7: Analyses with the Assumption of Exchangeability 
So far, our analyses have been based on the fact that exchangeability does not hold. In the 
following sections, we assume exchangeability and investigate the impact on the analyses this 
far. The analyses involving exchangeability has been dealt with in Gadbury et al. (2004).  In the 
following sections, we will explain the transition from the analyses without exchangeability and 
restate (where necessary and without proofs) the key results from the Gadbury et al. (2004) 
paper. As a consequence of exchangeability, equations (1.48) through (1.51) become   
1 1φ = ω − ∆                                                 (1.68) 
2 2φ = ω + ∆                                                (1.69) 
3 3φ = ω + ∆                                                (1.70) 
4 4φ = ω − ∆                                                (1.71) 
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where i ki k i′φ = φ = φ  for 1,2,3,4;  1,2i k k′= ≠ =  - for instance 1 11 21φ = φ = φ , 2 12 22φ = φ = φ , 
3 11 23φ = φ = φ  -  and thus, 14 23TC CT∆ = ∆ = ∆ = β − β . From equations (1.69) through 
(1.72), we have the following adaptations. 
 
4.7.1: Bounds for the Probability of Negative Effect with Exchangeability 
           Earlier, we saw that [ ]2 1 1,L Uω ∈  where ( ) ( ){ }1 12 22 13 23max 0,  0.5L = φ + φ − φ + φ    
and ( ) ( ) ( ) ( ){ }1 11 21 22 12 14 2412 22min 0.5 ,  0.5U = φ + φ + φ + φ φ + φ + φ + φ       . With the 
assumption of exchangeability, 11 21 1φ = φ = θ , 12 22 2φ = φ = θ , 13 23 3φ = φ = θ  and 
14 24 4φ = φ = θ  where the , 1,2,3,4i iθ =  are used as in Gadbury et al. (2004).  Note that 
( )1 1 20 ,  Y 0P Xθ = = = , ( )2 1 20 ,  Y 1P Xθ = = = , ( )3 1 21 ,  Y 0P Xθ = = =  and 
( )4 1 21 ,  Y 1P Xθ = = =  for the TC – CT crossover design and ( )31 1 20 ,  X 0P Xφ = = = , 
( )34 1 21 ,  X 1P Xφ = = = , ( )41 1 20 ,  0P Y Yφ = = =  and ( )44 1 21 ,  1P Y Yφ = = =  for the 
additional TT – CC design.  Thus, 1 1 and L U  become 1 1,
E EL U    where  
[ ]{ } { }1 2 3 2 3 1max 0,  0.5 2 2 max 0,  EL L= θ − θ = θ − θ =  and 
( ) ( ){ } { }1 1 2 2 4 1 2 2 4 2min 0.5 2 2 ,  0.5 2 2 min ,  EU U= θ + θ θ + θ = θ + θ θ + θ = .  
Thus, { }1 2 3max 0,  EL = θ − θ  and { }2 1 2 2 4min ,  EU = θ + θ θ + θ . These are same bounds 
specified in Gadbury et al. (2004).   
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4.7.2: Refined Bound for the Probability of Negative Effect 
              Previously, we derived (1.53) that, ( )( )2 12 220.5 TC CTω = φ + φ − ∆ + ∆ . Imposing the 
exchangeability assumption leads to 2 2ω = θ − ∆  where  2 12 22θ = φ = φ  and 
14 23TC CT∆ = ∆ = ∆ = β − β .  This constitutes part of equation (4) in Gadbury et al. (2004) where 
14 23∆ = δ = β − β . Furthermore, the assumption of exchangeability results in symmetry of 
probabilities on Table 4.4. Let ( )1p E X=  and ( )2p E Y=  be the mean of the marginal 
distributions of X  and Y . Using symmetry, it can be proven that, 
1 31 1 34 2 41 2 441  and 1p p p p− φ = − − φ − φ = − − φ . Applying these equations to the bounds 
[ ]2 2,L U  gives bounds 2 2,E EL U    where, { }2 2 1 3 2 4min ,EL p p= θ − − θ − θ  and 
{ }2 2 1 3 2 4min ,EU p p= θ + − θ − θ . These are the same bounds given in (Proposition 3 of) 
Gadbury et al. (2004). 
Having developed the theory, the next sections follow with a simulated illustrative 
example. We will illustrate the results outlined above on a simulated count data. We first state a 
joint probability distribution similar to that given on Table 4.4. Then, using Table 4.4, we 
simulate the observed count data, from which our maximum likelihood estimates are found using 
the optim procedure in R (www.r-project.com). Because the actual probabilities are known, we 
are able to find the true probability quantities and compare these with their respective estimates. 
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4.7.4: Illustrative Example 5: Simulated Observed Count Data  
In the following example, we first state a joint probability distribution, ijβ (for , 1,2,3,4i j = ), 
similar to that given on Table 4.4. Table 4.12 below gives the actual joint probability distribution 
of the potential outcomes for response variable X  and Y .  
Table 4.12: Joint probabilities distribution obtained from the simulated example involving 600 
subjects with focus on period 1 marginals using the TC – CT design without the exchangeability 
assumption  
 Period 2  
For an 
Individual ( ) ( )
 
2 2, 0,0
T C
x y =  ( ) ( ) 2 2, 0,1
T C
x y =  ( ) ( ) 2 2, 1,0
T C
x y =  ( ) ( ) 2 2, 1,1
T C
x y =  
Marginal 
Total 
 
( ) ( )                    1 1, 0,0
T C
x y =  0.016 0.065 0.032 0.048 0.161 
Per. 1 ( ) ( )
  
1 1, 0,1
T C
x y =  0.032 0.016 0.113 0.081 0.242 
( ) ( ) 1 1, 1,0
T C
x y =  0.081 0.032 0.048 0.113 0.274 
( ) ( ) 1 1, 1,1
T C
x y =  0.032 0.129 0.081 0.081 0.323 
Marginal 
Total 0.161 0.242 0.274 0.323 1.000 
 
 
Clearly, exchangeability condition does not hold. The marginal probabilities are 
( ) ( )1 2 3 4, , , 0.161,0.242,0.274,0.323ω ω ω ω = . The parameter values for the unmatched design 
are ( )1 0.597p E X= =  and ( )2 0.565p E Y= = . Hence, the true average treatment T effect 
relative to treatment C is ( ) 0.032E D = .  A sample of 600 observations was generated from 
Table 4.12. Furthermore, from these 600 observations, 1 200n =  and 2 200n =  were randomly 
selected to receive treatment (T, C) and (C, T), in that order, respectively. Responses are either 
“1” – for success – or “0” – for failure. The values of the parameters under the TC – CT design 
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are 11 0.193φ = , 12 0.210φ = , 13 0.242φ =  and 14 0.355φ =  for the TC sequence and  
21 0.194φ = , 22 0.209φ = , 23 0.241φ =  and 24 0.356φ =  for the CT sequence. We also have 
0.065TC CT∆ + ∆ = − . The observed count data was also recorded. Table 4.13 below shows 
observed count data corresponding to the given outcomes.  
Table 4.13: Standard table of observed counts in a TC - CT crossover design for  
the simulated example 
Sequence ( )0 ,  0  ( )0 ,  1  ( )1 ,  0  ( )1 ,  1  Marginal Total 
( )1 TC  42 39 59 60 200 
( )2 CT  39 52 50 59 200 
 
Form Table 4.13, the maximum likelihood estimates of the probabilities, ˆ kiφ , were 
calculated using the numerical iterative method, optim  in R. The result is presented on Table 
4.14 below. 
Table 4.14: Estimates of probabilities of the observed data ˆ kiφ  for the TC - CT  
crossover design 
Sequence ( )0 ,  0  ( )0 ,  1  ( )1 ,  0  ( )1 ,  1  Marginal Total 
( )1 TC  0.2240 0.2295 0.2676 0.2789 1.0000 
( )2 CT  0.2118 0.2798 0.2417 0.2667 1.0000 
 
The standard errors for these estimated probabilities are given on Table 4.15 below. 
Table 4.15: Standard error of estimates ˆ kiφ for the TC – CT design 
Sequence ( )0 ,  0  ( )0 ,  1  ( )1 ,  0  ( )1 ,  1  
( )1 TC  0.0246` 0.0257 0.0250 0.0251 
( )2 CT  0.0246 0.0260 0.0245 0.0249 
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Using Table 4.14, the estimated average treatment effect, ( )E DΛ , was found to be 
0.0382. That is, on average, 3.82% subjects succeeded on treatment T relative to success on C.  
The actual value of the inestimable probability of negative effect, 2ω , is 0.242. In the theoretical 
analysis, we showed that this number is not measurable. Thus, we estimate bounds. The estimate 
of the lower bound for 2ω  is 1ˆ 0L =  and the estimate of the upper bound is 1ˆ 0.4535U = . That 
is, [ ]2 0,0.4535ω ∈ . Thus, between 0% and 45.4% of the subjects succeeded on C and failed on 
T.  
Furthermore, from the 600 observations, 3 100n =  and 4 100n =  were assigned to 
sequence TT and CC respectively. For the TT – CC design, the values of the parameters are 
31 0.129φ = , 32 0.274φ = , 33 0.274φ =  and 34 0.323φ =  for the TT sequence and  
41 0.177φ = , 42 0.258φ = , 43 0.258φ =  and 44 0.307φ =  for the CC sequence. Table 4.16, 
shows the added observed count data.  
Table 4.16: Standard table of observed counts in the a TC – CT – TT – CC design  
Sequence ( )0 ,  0  ( )0 ,  1  ( )1 ,  0  ( )1 ,  1  Marginal Total 
( )3 TT  12 25 27 36 100 
( )4 CC  20 30 20 30 100 
 
The multinomial parameter estimates using the observed count data on Table 4.16 are given as 
on Table 4.17 below 
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Table 4.17: Estimates of probabilities of the observed data ˆ kiφ  for the  
TC – CT – TT – CC design  
Sequence ( )0 ,  0  ( )0 ,  1  ( )1 ,  0  ( )1 ,  1  Marginal Total 
( )1 TC  0.2086 0.2167 0.2823 0.2925 1.0000 
( )2 CT  0.2113 0.2796 0.2139 0.2952 1.0000 
( )3 TT  0.1461 0.2792 0.3281 0.2467 1.0000 
( )4 CC  0.2259 0.2650 0.1334 0.3757 1.0000 
 
The standard errors for these estimated probabilities given on Table 4.17 are as shown on Table 
4.18 below 
Table 4.18: Standard errors of estimates ˆ kiφ for the TC – CT –  
TT – CC design 
Sequence ( )0 ,  0  ( )0 ,  1  ( )1 ,  0  ( )1 ,  1  
( )1 TC  0.0229 0.0233 0.0239 0.0246 
( )2 CT  0.0230 0.0249 0.02224 0.0243 
( )3 TT  0.0346 0.0365 0.0378 0.0351 
( )4 CC  0.0369 0.0366 0.0276 0.0335 
 
The estimated refined lower bound for 2ω  is 2ˆ 0.0161L =  and the estimate of the upper 
bound is 2ˆ 0.4145U = . This constitutes a 12.14% reduction on the previous bounds 
[ ]1 1ˆ ˆ, 0,0.4535L U  =   for the probability of negative effect, 2ω , established under the TC – CT 
crossover design. Thus, with a sample size of 600, we got a tighter bound upon addition of the 
information from subjects who stayed on the same treatments over the two periods. 
We did not consider the case when exchangeability holds because an example was 
outlined in Gadbury et al. (2004). 
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CHAPTER 5 - Summary and Future Challenges 
5.1: Summary 
This dissertation was centered on using the potential outcomes method to estimate the 
individual treatment effect variability and a probability of a negative treatment effect in multiple 
time point settings. The assumptions were: no carryover effects, no covariate effects, no missing 
data, and a particular assumption about independence of time effects for different potential 
outcome variables.  For a quantitative response, we analyzed a two-treatment, two-periods and a 
two-treatment, three-periods crossover design. We saw that estimation of the individual 
treatment effect variable was not possible with the two-treatment, two-periods crossover design 
unless we add the information provided by subjects under an added parallel design. Under the 
two-treatment, three-periods design, we proposed an estimate for the finite population treatment 
effect mean and variance.  Furthermore, we estimated a parameter for the probability of negative 
effect. A simulated blood pressure data was use for illustration.   
In the qualitative section, a binary, “0 – 1,” response variable was analyzed. Using a 
given joint probability distribution of potential outcomes, we expressed the probability of the 
observed outcomes under a two treatment, two periods crossover design. Maximum likelihood 
estimates based on observed outcomes were found using an iterative numerical method. Using 
these estimates, we proposed bounds for an inestimable probability of a negative effect. Tighter 
bounds were obtained with information from subjects that received the same treatments over the 
two periods. Finally, for illustration, we used a simulated example of count data. 
  
 105 
5.2: Future Challenges  
We note that, the analyses assumed no carryover effect, no covariate effect and no 
missing data. It will be interesting to see how the results are affected when there is carryover 
effect. In addition, covariates like gender, age and others may be factored in. For a brief 
consideration, let’s assume carryover effects are present. The next section introduces the 
analyses of a two treatment, two periods TC – CT crossover design when carryover effects are 
added. 
 
5.2.1: Potential Outcome Framework with Carryover Effect – Quantitative Response 
Variable 
           In Section 1.3.2, we presented the potential outcome framework when there is no 
carryover effect. Such a framework was defined as 
1 11 1 11 1 12 1 12
2 2 1 2 2 1 2 2 2 2 2 2
Subject Period 1 Period 2
1
2 n n n n n n n n
X t Y X t Y
n X t Y X t Y
+ + + +
+ + + +
    
τ τ
τ τ
 
 with potential outcomes ( )1 1,  i i i iX t Y τ+ +  for period 1 and ( )2 2,  i i i iX t Y τ+ +  for period 2 
( )1, 2,..., 2i n= .  
Now, assume there is the effect carryover. The first question arises on how to factor the 
carryover effect into the potential outcome framework. For instance, for the thi  subject, let 
1, 1i j−ξ  and 2, 1i j−ξ  denote the carryover effects of treatments C to T and T to C, respectively, 
administered in the thj  period. We assumed 1,0 0iξ =  and 2,0 0iξ = . In a design involving more 
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than two periods or with the added TT and CC designs, we may further define the carryover 
effect from treatment T to T and treatment C to C. 
For a two treatment, two periods design, a possible potential outcomes framework is  
1 11 1 11 1 12 1,1 1 12 2,1
2 2 1 2 2 1 2 2 2 1,1 2 2 2 2,1
Subject Period 1 Period 2
1
2
i i
n n n n n n i n n i
X t Y X t Y
n X t Y X t Y
τ ξ τ ξ
τ ξ τ ξ
+ + + + + +
+ + + + + +
      
 That is, the potential outcomes are ( )1 1,  i i i iX t Y τ+ +  for period 1 and 
( )2 1,1 2 2,1,  i i i i i iX t Yξ τ ξ+ + + +  for period 2 ( )1, 2,..., 2i n= .   
Using this framework for potential outcome in a TC – CT randomization, the observed outcomes 
framework become 
1 2 2,1
1 2 1,1
                              Period
                             1    2
  
Sequence 
  
i i i i i
i i i i i
T C X t Y
C T Y X t
τ ξ
τ ξ
+ + +
+ + +
 
The observed treatment effect is then defined accordingly. Detailed development on this topic 
and more is left for further research. 
In the situation with binary outcomes, carryover effect could imply the marginals, at the two time 
periods, are not the same as assumed on Table 4.4. 
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5.2.2. Use of covariates 
As noted in Section 2.1 for quantitative outcomes in the TC, CT, TT, CC design, the 
variance of individual effects could be estimated assuming independence of t  and τ . If these are 
not independent, then only bounds for the variance can be estimated. Producing these bounds and 
their estimates would be interesting for future research. When covariates (i.e., variables not 
affected by treatment such as baseline measurements) are available, they may be used to tighten 
bounds. In such cases, a large lower bound for the variance of individual effects may then be 
evidence of substantive individual treatment effect heterogeneity.  
 
5.1.3 Missing Data  
Missing data may occur in a multiple time point trial when individuals drop out for various 
reasons. It has been assumed herein that complete data are available, that is, individuals complete 
the trial. This is equivalent to data missing completely at random. Missing data due to drop out 
might not be missing at random and this fact would add complexity in even obtaining unbiased 
estimates of the mean treatment effect. How such missing data would affect the variance of 
individual effects (or bounds for this variance) could be another avenue of future investigation. 
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Proposition 3.3 
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where,  
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Appendix D - Bounds for the True Variance of Individual 
Treatment Effects  
4.4.1: Bounds for the Variance of Individual Treatment Effects 
Previously, we had that the variance of the true individual treatment effect is given as 
( ) ( ) ( )
( ) ( )
( ) ( )
22
2
2 3 3 2
2 2 3 3 2 3
           
           1 1 2
Var D E D E D= −
= ω + ω − ω − ω
= ω − ω + ω − ω + ω ω
 
Using the TC – CT design, ( )Var D  cannot be estimated since ( )2 3ω + ω  cannot be estimated. 
That is,  
( ) ( ) ( )( )22 3Var D E D= ω + ω −  
However, if we denote an estimate of ( )Var D  as ( )Var DΛ , then, we would have, 
( ) ( ) ( ) ( ) 213 23 12 22ˆ ˆ ˆ ˆ 0.5 TC CTVar D E DΛ Λ = φ + φ + φ + φ − ∆ + ∆ −  
 
 
where ( ) ( )2 3 13 23 12 23ˆ ˆ ˆ ˆ0.5 TC CTΛω + ω = φ + φ + φ + φ − ∆ + ∆  is derived from equations (1.45), 
(1.46), (1.49) and (1.50). ( )Var DΛ  cannot be measured using the TC – CT design even with the 
assumption of exchangeability since ( )TC CT∆ + ∆  still persists. However, considering the fact 
that, an estimate of 2 3ω + ω  can be expressed as: 
( ) ( )2 3 13 23 12 23ˆ ˆ ˆ ˆ0.5 TC CTΛω + ω = φ + φ + φ + φ − ∆ + ∆                           (1.72) 
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Additional information from the TT – CC design can be used to establish bounds for 
( )TC CT∆ + ∆  and hence for ( )Var D . The next theorem uses the knowledge from the additional 
TT – CC design to bound ( )TC CT∆ + ∆  and subsequently, ( )Var D
Λ
. 
 
 
Proposition 4.6.3 
Given that ( ) ( ){ }31 34 41 44min 1 ,1TC CT∆ + ∆ ≤ − φ + φ − φ + φ , the true variance of the 
individual treatment effects, ( ) ,Var D L U∗ ∗ ∈    
 where, ( ) ( ) ( ){ }{ }12 22 13 23 31 34 41 44max 0,0.5 min 1 ,1L∗  = φ + φ + φ + φ − − φ + φ − φ + φ   and  
( ) ( ) ( ){ }12 22 13 23 31 34 41 440.5 min 1 ,1U ∗ = φ + φ + φ + φ + − φ + φ − φ + φ  
Proof: 
Previously, we established that  
( ) ( ) ( )( )
( ) ( ) ( )
2
2 3
2
13 23 12 22            0.5 TC CT
Var D E D
E D
Λ
= ω + ω −
 
= φ + φ + φ + φ − ∆ + ∆ −  
 
 
( )( )2E D is always positive. Thus, ( ) ( ) ( )13 23 12 220 0.5 TC CTVar D≤ ≤ φ + φ + φ + φ − ∆ + ∆  
Using the fact that ( ) ( ){ }31 34 41 44min 1 ,1TC CT∆ + ∆ ≤ − φ + φ − φ + φ , it follows that, 
( ) ( ){ } ( ) ( ) ( ){ }31 34 41 44 31 34 41 44mi n 1 ,1 min 1 ,1TC CT⇒ − − φ + φ − φ + φ ≤ ∆ + ∆ ≤ − φ + φ − φ + φ
. 
 Thus, ( ) ,Var D L U∗ ∗ ∈    
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 where, ( ) ( ) ( ){ }{ }12 22 13 23 31 34 41 44max 0,0.5 min 1 ,1L∗ = φ + φ + φ + φ − − φ + φ − φ + φ  and  
( ) ( ) ( ){ }12 22 13 23 31 34 41 440.5 min 1 ,1U ∗ = φ + φ + φ + φ + − φ + φ − φ + φ                                        
 
4.7.3: Bound for the Variance of the Individual Treatment Effect with Exchangeability 
          Using the exchangeability assumption, the bounds for the true variance of the individual 
treatment effect ,L U∗ ∗    given become ,E EL U
∗ ∗    where,  
Thus, ( ) ,Var D L U∗ ∗ ∈    
 where, 
( ) ( ) ( ){ }{ }
{ }{ }
12 22 13 23 31 34 41 44
2 3 1 3 2 4
*
max 0,0.5 min 1 ,1
   max 0, min ,
   E
L
p p
L
∗
= φ + φ + φ + φ − − φ + φ − φ + φ
= θ + θ − − θ − θ
=
 and  
( ) ( ) ( ){ }
{ }
12 22 13 23 31 34 41 44
2 3 1 3 2 4
*
0.5 min 1 ,1
    min ,
    E
U
p p
U
∗
= φ + φ + φ + φ + − φ + φ − φ + φ
= θ + θ + − θ − θ
=
                                                 
Thus, { }{ }* 2 3 1 3 2 4max 0, min ,EL p p= θ + θ − − θ − θ  
 and { }* 2 3 1 3 2 4min ,EU p p= θ + θ + − θ − θ , 
 where, ( )1 1 20 ,  Y 0P Xθ = = = , ( )2 1 20 ,  Y 1P Xθ = = = , ( )3 1 21 ,  Y 0P Xθ = = =  and 
( )4 1 21 ,  Y 1P Xθ = = = . 
 
 
 
